<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Open Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">Open Biol</journal-id>
<journal-id journal-id-type="publisher-id">RSOB</journal-id>
<journal-id journal-id-type="hwp">royopenbio</journal-id>
<journal-title-group>
<journal-title>Open Biology</journal-title>
</journal-title-group>
<issn pub-type="epub">2046-2441</issn>
<publisher>
<publisher-name>The Royal Society</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32574549</article-id>
<article-id pub-id-type="pmc">7333886</article-id>
<article-id pub-id-type="doi">10.1098/rsob.200105</article-id>
<article-id pub-id-type="publisher-id">rsob200105</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>1001</subject>
<subject>15</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
<subj-group subj-group-type="leader">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease</article-title>
<alt-title alt-title-type="short">KEAP1, a sensor and a drug target</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dayalan Naidu</surname>
<given-names>Sharadha</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-0316-9859</contrib-id>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>Albena T.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
<xref ref-type="corresp" rid="cor1"></xref>
</contrib>
</contrib-group>
<aff id="af1"><label>1</label><institution>Jacqui Wood Cancer Centre, Division of Cellular Medicine, School of Medicine, University of Dundee</institution>, <addr-line>Dundee</addr-line>, <country>UK</country></aff>
<aff id="af2"><label>2</label><institution>Department of Pharmacology and Molecular Sciences and Department of Medicine, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, MD</addr-line>, <country>USA</country></aff>
<author-notes>
<corresp id="cor1">e-mail: <email>a.dinkovakostova@dundee.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>24</day>
<month>6</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>10</volume>
<issue>6</issue>
<elocation-id>200105</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>4</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 The Authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<ali:license_ref specific-use="version-of-record" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<ali:license_ref specific-use="text-data-mining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>Published by the Royal Society under the terms of the Creative Commons Attribution License <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>, which permits unrestricted use, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="rsob-10-200105.pdf"></self-uri>
<self-uri xlink:href="rsob200105.thumb.gif" xlink:role="icon"></self-uri>
<self-uri content-type="reviewer_comments" xlink:href="rsob200105_review_history.pdf"></self-uri>
<abstract>
<p>Redox imbalance and persistent inflammation are the underlying causes of most chronic diseases. Mammalian cells have evolved elaborate mechanisms for restoring redox homeostasis and resolving acute inflammatory responses. One prominent mechanism is that of inducing the expression of antioxidant, anti-inflammatory and other cytoprotective proteins, while also suppressing the production of pro-inflammatory mediators, through the activation of transcription factor nuclear factor-erythroid 2 p45-related factor 2 (NRF2). At homeostatic conditions, NRF2 is a short-lived protein, which avidly binds to Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 functions as (i) a substrate adaptor for a Cullin 3 (CUL3)-based E3 ubiquitin ligase that targets NRF2 for ubiquitination and proteasomal degradation, and (ii) a cysteine-based sensor for a myriad of physiological and pharmacological NRF2 activators. Here, we review the intricate molecular mechanisms by which KEAP1 senses electrophiles and oxidants. Chemical modification of specific cysteine sensors of KEAP1 results in loss of NRF2-repressor function and alterations in the expression of NRF2-target genes that encode large networks of diverse proteins, which collectively restore redox balance and resolve inflammation, thus ensuring a comprehensive cytoprotection. We focus on the cyclic cyanoenones, the most potent NRF2 activators, some of which are currently in clinical trials for various pathologies characterized by redox imbalance and inflammation.</p>
</abstract>
<kwd-group>
<kwd>KEAP1</kwd>
<kwd>NRF2</kwd>
<kwd>cysteine</kwd>
<kwd>anti-inflammatory</kwd>
<kwd>antioxidant</kwd>
<kwd>redox</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Cancer Research UK</institution>
<institution-id>http://dx.doi.org/10.13039/501100000289</institution-id>
</institution-wrap>
</funding-source>
<award-id>C20953/A18644</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>June 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1">
<label>1.</label>
<title>Introduction</title>
<p>All living organisms are vulnerable to various chemical stressors derived from endogenous and exogenous sources, such as reactive oxygen species (ROS), reactive nitrogen species (RNS) and reactive lipid species (RLS), which play important roles in cell signalling, but when produced in excess lead to oxidative stress. Oxidation–reduction (redox) reactions are common in biology, and the maintenance of redox homeostasis is vital for the correct functioning of most biological processes [<xref ref-type="bibr" rid="RSOB200105C1">1</xref>]. Oxidative stress occurs when there is an excess of oxidants, and the antioxidants are insufficient for restoring the intracellular redox balance [<xref ref-type="bibr" rid="RSOB200105C2">2</xref>]. Some examples of sources of exogenous oxidative stressors are environmental pollutants, ultraviolet (UV) and ionizing radiation, and genotoxic agents. Endogenous stressors, usually produced intracellularly, are derived from metabolic processes such as mitochondrial respiration and inflammation. Exposure to these chemically reactive species promotes cellular macromolecular damage. Chronic oxidative stress has been implicated in the development and exacerbation of neurodegenerative diseases [<xref ref-type="bibr" rid="RSOB200105C3">3</xref>,<xref ref-type="bibr" rid="RSOB200105C4">4</xref>], cancer [<xref ref-type="bibr" rid="RSOB200105C5">5</xref>,<xref ref-type="bibr" rid="RSOB200105C6">6</xref>], diabetes [<xref ref-type="bibr" rid="RSOB200105C7">7</xref>,<xref ref-type="bibr" rid="RSOB200105C8">8</xref>], autoimmune [<xref ref-type="bibr" rid="RSOB200105C9">9</xref>], cutaneous [<xref ref-type="bibr" rid="RSOB200105C10">10</xref>–<xref ref-type="bibr" rid="RSOB200105C12">12</xref>], pulmonary [<xref ref-type="bibr" rid="RSOB200105C13">13</xref>,<xref ref-type="bibr" rid="RSOB200105C14">14</xref>] and cardiovascular [<xref ref-type="bibr" rid="RSOB200105C14">14</xref>,<xref ref-type="bibr" rid="RSOB200105C15">15</xref>] diseases, infection [<xref ref-type="bibr" rid="RSOB200105C16">16</xref>], inflammation [<xref ref-type="bibr" rid="RSOB200105C17">17</xref>], as well as aging [<xref ref-type="bibr" rid="RSOB200105C18">18</xref>–<xref ref-type="bibr" rid="RSOB200105C20">20</xref>]. Cells have evolved several mechanisms to combat these relentless chemical insults in order to reinstate the redox homeostasis. The activation of the KEAP1/NRF2/ARE pathway is one such mechanism, which orchestrates the upregulation of antioxidant, anti-inflammatory and other cytoprotective proteins.</p>
</sec>
<sec id="s2">
<label>2.</label>
<title>The NRF2/KEAP1/ARE cytoprotective pathway</title>
<p>Under homeostatic conditions, the transcription factor nuclear factor erythroid-2 p45-related factor 2 (NRF2) (<xref ref-type="fig" rid="RSOB200105F1">figure 1</xref><italic>a</italic>), is continuously ubiquitinated and targeted for 26S proteasomal degradation by its negative regulator Kelch-like (ECH)-associated protein 1 (KEAP1) (<xref ref-type="fig" rid="RSOB200105F1">figure 1</xref><italic>b</italic>), which is a substrate adaptor for the Cullin 3 (CUL3)-ring box 1 (RBX1) E3-ubiquitin ligase system [<xref ref-type="bibr" rid="RSOB200105C21">21</xref>]. Electrophiles from endogenous and exogenous sources or other small molecules (termed inducers) which activate NRF2 are able to do so via inactivating KEAP1 by reacting with its cysteine(s) residues or by disrupting the KEAP1:NRF2 protein–protein interaction (PPI) interface [<xref ref-type="bibr" rid="RSOB200105C22">22</xref>,<xref ref-type="bibr" rid="RSOB200105C23">23</xref>]. Consequently, KEAP1 is unable to target the transcription factor for degradation. The interactions between KEAP1 and NRF2 and the effect of inducers on NRF2 stabilization can be visualized by the imaging of live cells expressing KEAP1 and NRF2, each fused to a fluorescent protein [<xref ref-type="bibr" rid="RSOB200105C24">24</xref>,<xref ref-type="bibr" rid="RSOB200105C25">25</xref>]. Following KEAP1 inactivation, the newly synthesized or free NRF2 is able to accumulate and translocate into the nucleus where it heterodimerizes with a small musculoaponeurotic fibrosarcoma (sMAF) protein and binds to the antioxidant response elements (ARE) with the consensus sequence 5′-TGACxxxGC-3′ found in the promoters of its target genes [<xref ref-type="bibr" rid="RSOB200105C21">21</xref>]. The 605-amino acid long NRF2 protein belongs to the family of the Cap'n’Collar (CnC) basic leucine zipper (bZIP) transcription factors, and is composed of seven NRF2-ECH (Neh) domains which are highly conserved (<xref ref-type="fig" rid="RSOB200105F1">figure 1</xref><italic>a</italic>). The N-terminally lying Neh2 domain of NRF2 contains two KEAP1 (low- and high-affinity) binding motifs, which are the sequences DLG and ETGE, respectively [<xref ref-type="bibr" rid="RSOB200105C26">26</xref>].
<fig id="RSOB200105F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>(<italic>a</italic>) Domain structure of human NRF2. There are seven NRF2-ECH (Neh) domains found within NRF2. The N-terminal Neh2 domain contains the KEAP1 binding motifs DLG and ETGE. The Neh4 and 5 domains within the transcription factor are required for its transactivation and the proteins that have exhibited binding to this region are CREB (cAMP responsive element binding protein) binding protein (CBP), AXIN1, silencing mediator of retinoic acid and thyroid hormone receptor (SMRT1), Receptor-associated coactivator 3 (RAC3), nuclear matrix protein (NRP/B), casein kinase 2 (CK2), Brahma-related gene 1 (BRG1) and mediator complex subunit 16 (MED16). The Neh7 domain found in the middle of the NRF2 protein has been shown to interact with retinoid X receptor alpha (RXRα) as well as retinoic acid receptor alpha (RARα). Two motifs, DSGIS and DSAPGS are found within the Neh6 domain, and are important for the binding of β-TrCP to facilitate NRF2-degradation, where the binding is promoted upon glycogen synthase kinase β (GSK3-β)-mediated phosphorylation of the DSGIS motif. C-Jun N-Terminal Kinase (JNK) binds to the Neh6 domain and phosphorylates S335. The Neh1 domain comprises of the DNA-binding motif and the binding region for the sMAF proteins. The carboxy-terminal Neh3 domain is also important for transactivation of NRF2 and chromodomain helicase DNA binding protein 6 (CHD6) interacts with this domain. (<italic>b</italic>) Domain structure of human KEAP1. The KEAP1 protein is a substrate adaptor for the CUL3-based E3 ligase, and is sectioned into five domains: (1) N-terminal region (NTR); (2) Broad complex, tramtrack, and Bric à Brac (BTB) domain allows for the homodimerization of KEAP1 monomers as well as CUL3 binding; (3) Intervening region (IVR); (4) Kelch domain (KELCH) is a structure consisting of a six-bladed β-propeller, where one KELCH subunit within the KEAP1 homodimer binds to the DLG motif and the other binds to the ETGE motifs found within the Neh2 domain of NRF2; and (5) C-terminal region (CTR). The black vertical lines represent the positions of the 27 cysteine residues present within the protein. Cartoon and surface representations of the BTB (pale pink) (PDB ID: 4CXI), IVR (pale yellow) (modelled) and KELCH (pale blue) (PDB ID: 5WFV) were drawn with UCSF ChimeraX software using X-Crystallographic images deposited into the Protein Data Bank (rscb.org) or modelled using the web-based I-TASSER platform.</p></caption><graphic xlink:href="rsob-10-200105-g1"></graphic></fig></p>
<sec id="s2a">
<label>2.1.</label>
<title>NRF2-mediated antioxidant effects</title>
<p>Together, the NRF2 target genes (over 250) are involved in mounting a cellular defence response by encoding a large network of proteins, some of which catalyse phase I, II and III cytoprotective detoxification reactions, while others have antioxidant and anti-inflammatory properties [<xref ref-type="bibr" rid="RSOB200105C27">27</xref>]. NRF2 controls the cellular redox homeostasis by regulating key enzymes and proteins involved in processes such as the synthesis, utilization and regeneration of glutathione (GSH), thioredoxin (TXN), peroxiredoxin and NADPH production [<xref ref-type="bibr" rid="RSOB200105C28">28</xref>]. The activity of NRF2 is a major determining factor of the cellular redox state.</p>
<p>GSH is an essential thiol-based intracellular tripeptide that plays a vital role in the defence against cellular oxidative stress through its ability to neutralize ROS/RNS as well as electrophilic species [<xref ref-type="bibr" rid="RSOB200105C29">29</xref>]. Perturbed glutathione homeostasis has been implicated in numerous pathological conditions [<xref ref-type="bibr" rid="RSOB200105C30">30</xref>,<xref ref-type="bibr" rid="RSOB200105C31">31</xref>]. NRF2 regulates the gene expression of the catalytic subunit GCLC and the modifier subunit GCLM of γ-glutamate-cysteine ligase (GCL), the enzyme catalysing the rate-limiting step in the GSH biosynthesis [<xref ref-type="bibr" rid="RSOB200105C32">32</xref>], as well as the gene expression of the cystine/glutamate antiporter (SLC7A11, system xc−) [<xref ref-type="bibr" rid="RSOB200105C33">33</xref>] that is responsible for the import of cystine, which in turn is converted to cysteine, a GSH precursor. The flux of glutamine into anabolic pathways is enhanced under conditions of NRF2 activation [<xref ref-type="bibr" rid="RSOB200105C34">34</xref>] thus providing glutamate, the second GSH precursor; of note, glutamate is also necessary for the import of cystine by system xc−. The transporter SLC6A9, another NRF2-regulated gene, provides the third GSH precursor, glycine [<xref ref-type="bibr" rid="RSOB200105C35">35</xref>]. In addition to the biosynthesis of GSH, NRF2 also regulates the regeneration of GSH. The transcription factor controls the expression of glutathione peroxidase (GPX), which detoxifies peroxides to produce oxidized glutathione (GSSG). In turn, GSSG is a substrate for the NRF2-target glutathione reductase (GSR), which regenerates GSH from GSSG using NADPH as a hydride donor. Importantly, NRF2 is also involved in the regulation of cellular NADPH levels by controlling the gene expression of the four main enzymes involved in the generation of NADPH: isocitrate dehydrogenase 1 (IDH1), 6-phosphogluconate dehydrogenase (PGD), glucose-6-phosphate dehydrogenase (G6PD) and malic enzyme 1 (ME1) [<xref ref-type="bibr" rid="RSOB200105C34">34</xref>,<xref ref-type="bibr" rid="RSOB200105C36">36</xref>].</p>
<p>The role of NRF2 in the biosynthesis and maintenance of GSH is particularly important in the brain [<xref ref-type="bibr" rid="RSOB200105C37">37</xref>,<xref ref-type="bibr" rid="RSOB200105C38">38</xref>], and may also affect the metabolic glutamate–glutamine cycle that allows the inter-cellular exchange of these amino acids between neurons and astrocytes [<xref ref-type="bibr" rid="RSOB200105C39">39</xref>]. During neuronal development, expression of <italic>NFE2L2</italic> (the gene encoding NRF2) is repressed by promoter methylation [<xref ref-type="bibr" rid="RSOB200105C40">40</xref>], and NRF2 activity in astrocytes is critical for neuronal protection against oxidative stress [<xref ref-type="bibr" rid="RSOB200105C41">41</xref>]. In rapidly proliferating cells, such as cancer cells, NRF2 activation channels glucose through the pentose phosphate pathway [<xref ref-type="bibr" rid="RSOB200105C34">34</xref>], a major source of reducing equivalents for GSH regeneration, but also increases consumption of glutamate for GSH biosynthesis and glutamate secretion by system xc− [<xref ref-type="bibr" rid="RSOB200105C42">42</xref>].</p>
</sec>
<sec id="s2b">
<label>2.2.</label>
<title>NRF2-mediated anti-inflammatory effects</title>
<p>In addition to antioxidant, the activation of NRF2 has anti-inflammatory effects, which have been consistently observed in cellular and animal models, as well as in human intervention trials with pharmacological NRF2 activators. Thus, a recent analysis of peripheral blood mononuclear cells (PBMCs) isolated from human subjects following intervention with sulforaphane, a classical NRF2 activator, reported an increase in the expression of NRF2-target genes (i.e. NQO1, HO1, AKR1C1), which was accompanied by a decrease in inflammatory markers (i.e. IL-6, TNFα, IL-1β, COX2) [<xref ref-type="bibr" rid="RSOB200105C43">43</xref>]. NRF2 is critical for the resolution of inflammation. The endogenous mildly electrophilic anti-inflammatory mitochondrial immunometabolite itaconate, which accumulates to millimolar concentrations during the metabolic reprogramming in activated macrophages [<xref ref-type="bibr" rid="RSOB200105C44">44</xref>,<xref ref-type="bibr" rid="RSOB200105C45">45</xref>], is an NRF2 activator. In turn, NRF2 represses the expression of pro-inflammatory cytokines and the type I interferon (IFN) response, promoting the resolution of inflammation [<xref ref-type="bibr" rid="RSOB200105C45">45</xref>–<xref ref-type="bibr" rid="RSOB200105C49">49</xref>]. Interestingly, NRF2 is also important for the execution of inflammation. Itaconate is downregulated in dysfunctional macrophages from hypercholesterolemic mice, and the levels of NRF2 and the expression of its target genes are lower in lipopolysaccharide (LPS)-stimulated macrophages isolated from mice fed high-fat diet (HFD) compared to standard fat diet (SFD) [<xref ref-type="bibr" rid="RSOB200105C50">50</xref>]. These findings illustrate that systemic metabolic changes can suppress NRF2 and consequently interfere with metabolic reprogramming in immune cells, which is necessary for their effector functions.</p>
<p>Thus, the activation of NRF2 is an attractive therapeutic strategy to combat diseases characterized by chronic oxidative stress and inflammation as it provides a multi-targeted approach [<xref ref-type="bibr" rid="RSOB200105C51">51</xref>,<xref ref-type="bibr" rid="RSOB200105C52">52</xref>]. Indeed, in recent years the pharmaceutical industry has invested heavily in the development of pharmacological modulators of the KEAP1/NRF2/ARE pathway, and there are currently more than 15 ongoing clinical trials as well as a number of compounds undergoing preclinical testing for various disease indications [<xref ref-type="bibr" rid="RSOB200105C23">23</xref>,<xref ref-type="bibr" rid="RSOB200105C53">53</xref>].</p>
</sec>
</sec>
<sec id="s3">
<label>3.</label>
<title>KEAP1</title>
<p>KEAP1 is a highly conserved cysteine-rich 624-amino acid protein sharing approximately 92% sequence homology among the mammalian species (<xref ref-type="fig" rid="RSOB200105F2">figure 2</xref>). The existence of KEAP1 was predicted in the 1980s, more than a decade before its discovery. Following a series of extensive structure-activity studies using quantitative chemical biology approaches, Paul Talalay and his associates observed that numerous structurally diverse inducers of the cytoprotective enzymes NAD(P)H:quinone oxidoreductase (NQO1) and glutathione <italic>S</italic>-transferases (GSTs) have a common chemical property, namely sulfhydryl reactivity. This seminal discovery rationalized the perplexing lack of structural similarity among inducers, and led to the explicit suggestion that the primary cellular sensor with which inducers react is a protein endowed with highly reactive cysteines [<xref ref-type="bibr" rid="RSOB200105C54">54</xref>,<xref ref-type="bibr" rid="RSOB200105C55">55</xref>]. The identification of KEAP1 as a negative regulator of NRF2 by Masayuki Yamamoto and his colleagues in 1999 [<xref ref-type="bibr" rid="RSOB200105C56">56</xref>] immediately turned attention to the cysteine residues of KEAP1. Human KEAP1 has 27 cysteines, whereas mouse KEAP1 has 25, nine of which (red boxes in <xref ref-type="fig" rid="RSOB200105F2">figure 2</xref>) are flanked by basic amino acids. Cysteines are unique amino acids due to their sulfhydryl (thiol) functional group that performs various functions, including: (1) forming intra- and intermolecular covalent bonds with other cysteine thiols, (2) binding to metals and metalloids, and (3) undergoing reversible or irreversible oxidation upon reacting with oxidants [<xref ref-type="bibr" rid="RSOB200105C57">57</xref>]. The <italic>pKa</italic> value of cysteine (represented by the balance between the thiol and the thiolate anion) indicates its reactivity [<xref ref-type="bibr" rid="RSOB200105C58">58</xref>]. The lower the <italic>pKa</italic> value, where the formation of the thiolate anion is favoured, the cysteine reactivity increases. The presence of basic amino acids in close proximity to a cysteine decreases the <italic>pKa</italic>, hence increasing its reactivity [<xref ref-type="bibr" rid="RSOB200105C59">59</xref>,<xref ref-type="bibr" rid="RSOB200105C60">60</xref>]. The identification of highly reactive cysteines within KEAP1 that serve as inducer sensors [<xref ref-type="bibr" rid="RSOB200105C61">61</xref>] solved the puzzling fact that many inducers are active at sub-micromolar concentrations despite the millimolar intracellular concentrations of glutathione.
<fig id="RSOB200105F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Amino acid sequence alignment of various mammalian KEAP1. Alignment performed using the web-based Clustal Omega program found within uniprot.org. The Uniprot IDs are listed. Q14145 (human), Q9Z2X8 (mouse), P57790 (rat), Q684M4 (pig), Q5R774 (orangutan), H2QFB9 (chimpanzee). The cysteine residues are highlighted in yellow and the cysteine residues which have neighbouring basic amino acids are boxed in red. The amino acid sequence identity among these species is 92%.</p></caption><graphic xlink:href="rsob-10-200105-g2"></graphic></fig></p>
<sec id="s3a">
<label>3.1.</label>
<title>KEAP1 structure and its cysteine sensors</title>
<p>KEAP1 is a homodimeric protein belonging to the BTB (Broad complex, Tramtrack, Bric-á-brac)-Kelch family of proteins, which are named Kelch-like 1 to 42 (KLHL1–42). All members of this family are able to bind to CUL3 through their BTB domain (<xref ref-type="fig" rid="RSOB200105F1">figure 1</xref><italic>b</italic>). The BTB domain is necessary for KEAP1 homodimerization, and it has been reported that mutation of S104 to an alanine residue prevents its homodimerization and causes NRF2 accumulation in the nucleus [<xref ref-type="bibr" rid="RSOB200105C62">62</xref>]. There are three cysteines present in the KEAP1 BTB domain, C77, C151 and C171. Single mutants of each of the cysteines in the BTB domain to a serine behave like the wild-type (WT) KEAP1 in terms of their ability to repress NRF2-mediated gene expression [<xref ref-type="bibr" rid="RSOB200105C63">63</xref>]. C151 is the most well characterized in the literature. Under basal conditions, the KEAP1 C151S mutant is able to mediate the degradation of NRF2, similarly to the WT protein [<xref ref-type="bibr" rid="RSOB200105C63">63</xref>–<xref ref-type="bibr" rid="RSOB200105C65">65</xref>]. Zhang <italic>et al</italic>. found that the BTB domain of KEAP1 protected KEAP1 from ubiquitin-mediated degradation [<xref ref-type="bibr" rid="RSOB200105C66">66</xref>]. Interestingly, it has been shown by several groups that under basal conditions, when subjected to SDS-polyacrylamide gel electrophoresis (PAGE), WT KEAP1 migrates as two distinct species, one at approximately 65 kDa and the other at 130 kDa and that the slower migrating species does not appear within the C151S mutant [<xref ref-type="bibr" rid="RSOB200105C63">63</xref>,<xref ref-type="bibr" rid="RSOB200105C67">67</xref>]. Zhang and colleagues suggested that the slow migrating species of KEAP1 is due to posttranslational modifications occurring on the protein, as the mutation of C151S prevents its occurrence. We have observed a similar effect following treatment of cells with the double Michael acceptor dibenzylidene acetone (DBA) (S.D.N. 2016, unpublished observations). Fourquet <italic>et al</italic>. have shown that the intensity of this slower migrating KEAP1 species, which is resistant to reducing agents, is increased upon exposure to oxidants and nitrosative agents. These authors subsequently exposed lysates from induced cells to the reducing agent β-mercaptoethanol and observed a complete reduction in the intensified slower migrating species of KEAP1 hence suggesting that this species mainly consists of the oxidized form of KEAP1 [<xref ref-type="bibr" rid="RSOB200105C67">67</xref>]. Most recently, C151 from one subunit of the KEAP1 dimer was shown to form a methylimidazole crosslink with R135 from the second subunit upon accumulation of the reactive metabolite methylglyoxal, the concentration of which is increased in the plasma of diabetic patients [<xref ref-type="bibr" rid="RSOB200105C68">68</xref>]. In all cases, these post-translational modifications of C151 result in dimerization of KEAP1, accumulation of NRF2 and activation of the NRF2-driven cytoprotective transcriptional program. Of note, methylglyoxal is a precursor of highly damaging advanced glycation end-products, and NRF2 regulates the expression of glyoxalase 1, the enzyme that detoxifies methylglyoxal, thus protecting against glycation [<xref ref-type="bibr" rid="RSOB200105C69">69</xref>].</p>
<p>The cysteine residues of KEAP1, for which chemical modifications by various electrophiles and oxidants have been either demonstrated directly or implicated based on mutagenesis analyses, are summarized in <xref ref-type="table" rid="RSOB200105TB1">table 1</xref>. Some of the well-known NRF2 inducers that modify C151 are the isothiocyanate sulforaphane (SFN), the alkylating agent iodoacetamide (IAA), <italic>tert</italic>-butyl hydroquinone (tBHQ) and diethylmaleate (DEM) [<xref ref-type="bibr" rid="RSOB200105C64">64</xref>,<xref ref-type="bibr" rid="RSOB200105C65">65</xref>,<xref ref-type="bibr" rid="RSOB200105C73">73</xref>,<xref ref-type="bibr" rid="RSOB200105C92">92</xref>]. In 2010, using molecular modelling, McMahon <italic>et al</italic>. postulated that the reactivity of C151 in KEAP1 was due to the presence of five basic amino acid residues (H129, K131, R135, K150 and H154) located in close spatial proximity to C151 [<xref ref-type="bibr" rid="RSOB200105C64">64</xref>]. These five basic amino acids possess the ability to deprotonate the thiol group within C151, thereby, lowering its <italic>pKa</italic>. This results in the thiol group of C151 to exist as an anion under physiological pH conditions. Indeed, the authors showed that KEAP1 bearing the triple mutations K131M, R135M and K150M, lost the ability to sense electrophiles that specifically targeted C151 [<xref ref-type="bibr" rid="RSOB200105C64">64</xref>]. The crystal structure of the BTB domain of KEAP1 with the triterpenoid CDDO was solved in 2014 and deposited in the Protein Data Bank (rscb.org) with the accession number 4CXI [<xref ref-type="bibr" rid="RSOB200105C72">72</xref>]. We measured the distances of the 5 positively charged amino acids mentioned that were adjacent to C151 and found that R135 had the closest proximity to C151 with a distance of 3.6 angstroms (Å) (<xref ref-type="fig" rid="RSOB200105F3">figure 3</xref>), which further supports the findings reported by McMahon and colleagues [<xref ref-type="bibr" rid="RSOB200105C64">64</xref>].
<fig id="RSOB200105F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Structure of the human KEAP1 BTB domain. (<italic>a</italic>) Cartoon representation of the human KEAP1 BTB domain (pale pink) showing the side chain of CYS 151 in green. (<italic>b</italic>) The side chains of the basic amino acids (HIS 129, LYS 131, ARG 135, LYS 150 and HIS 154) adjacent to and surrounding the CYS 151 residues are represented with green stick drawings coloured by their elements. Structure drawn using UCSF ChimeraX software using the PDB accession 4CXI. The distances have been calculated in angstroms (Å) between these basic residues and CYS 151.</p></caption><graphic xlink:href="rsob-10-200105-g3"></graphic></fig>
<table-wrap id="RSOB200105TB1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Cysteine residues of KEAP1, for which chemical modifications by the indicated electrophiles and oxidants, have been implicated.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="1" rowspan="1"> </th><th align="left" colspan="1" rowspan="1">MCE-1</th><th align="left" colspan="1" rowspan="1">MCE-23</th><th align="left" colspan="1" rowspan="1">TBE-31</th><th align="left" colspan="1" rowspan="1">RTA-408</th><th align="left" colspan="1" rowspan="1">CDDO-Im</th><th align="left" colspan="1" rowspan="1">SF</th><th align="left" colspan="1" rowspan="1">PEITC</th><th align="left" colspan="1" rowspan="1">tBHQ</th><th align="left" colspan="1" rowspan="1">DEM</th><th align="left" colspan="1" rowspan="1">DMF</th><th align="left" colspan="1" rowspan="1">MEF</th><th align="left" colspan="1" rowspan="1">H<sub>2</sub>O<sub>2</sub></th><th align="left" colspan="1" rowspan="1">H<sub>2</sub>S</th><th align="left" colspan="1" rowspan="1">NO</th><th align="left" colspan="1" rowspan="1">OA-NO<sub>2</sub></th><th align="left" colspan="1" rowspan="1">SNAP</th><th align="left" colspan="1" rowspan="1">4-HNE</th><th align="left" colspan="1" rowspan="1">15d-PGJ<sub>2</sub></th><th align="left" colspan="1" rowspan="1">PGA<sub>2</sub></th><th align="left" colspan="1" rowspan="1">8-NO cGMP</th><th align="left" colspan="1" rowspan="1">As<sup>3+</sup></th><th align="left" colspan="1" rowspan="1">Cd<sup>2+</sup></th><th align="left" colspan="1" rowspan="1">Se<sup>4+</sup></th><th align="left" colspan="1" rowspan="1">Zn<sup>2+</sup></th><th align="left" colspan="1" rowspan="1">MeHg</th><th align="left" colspan="1" rowspan="1">Dex-Mes</th><th align="left" colspan="1" rowspan="1">1,2-NQ</th><th align="left" colspan="1" rowspan="1">MIND4-17</th><th align="left" colspan="1" rowspan="1">(Z)-LIG</th><th align="left" colspan="1" rowspan="1">Ox-LIG</th><th align="left" colspan="1" rowspan="1">DATS</th><th align="left" colspan="1" rowspan="1">NAPQI</th><th align="left" colspan="1" rowspan="1">Acrolein</th><th align="left" colspan="1" rowspan="1">XH</th><th align="left" colspan="1" rowspan="1">10-Shogaol</th><th align="left" colspan="1" rowspan="1">IAA</th><th align="left" colspan="1" rowspan="1">IAB</th><th align="left" colspan="1" rowspan="1">BMCC</th><th align="left" colspan="1" rowspan="1">ISO</th><th align="left" colspan="1" rowspan="1">Ebselen</th><th align="left" colspan="1" rowspan="1">4-OI</th><th align="left" colspan="1" rowspan="1">GSSG</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">C23</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C38</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C77</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td></tr><tr><td colspan="1" rowspan="1">C151</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C171</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C196</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C226</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td></tr><tr><td colspan="1" rowspan="1">C241</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C249</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C257</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C273</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C288</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C297</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td></tr><tr><td colspan="1" rowspan="1">C319</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td></tr><tr><td colspan="1" rowspan="1">C368</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td></tr><tr><td colspan="1" rowspan="1">C434</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td></tr><tr><td colspan="1" rowspan="1">C489</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C583</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C613</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">C622</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td></tr><tr><td colspan="1" rowspan="1">C624</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">♦</td></tr></tbody></table><table-wrap-foot><fn><p>3-ethynyl-3-methyl-6-oxocyclohexa-1,4-dienecarbonitrile (MCE-1) [<xref ref-type="bibr" rid="RSOB200105C70">70</xref>], 9a-ethynyl-3-oxo-9,9a-dihydro-3H-fluorene-2-carbonitrile (MCE-23) [<xref ref-type="bibr" rid="RSOB200105C70">70</xref>], (±)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a, octahydrophenanthrene-2,6-dicarbonitrile (TBE-31) [<xref ref-type="bibr" rid="RSOB200105C70">70</xref>], omaveloxolone (RTA-408) [<xref ref-type="bibr" rid="RSOB200105C71">71</xref>], 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) [<xref ref-type="bibr" rid="RSOB200105C65">65</xref>,<xref ref-type="bibr" rid="RSOB200105C72">72</xref>], 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO-Im) [<xref ref-type="bibr" rid="RSOB200105C65">65</xref>,<xref ref-type="bibr" rid="RSOB200105C72">72</xref>], sulforaphane (SF) [<xref ref-type="bibr" rid="RSOB200105C63">63</xref>–<xref ref-type="bibr" rid="RSOB200105C65">65</xref>,<xref ref-type="bibr" rid="RSOB200105C73">73</xref>,<xref ref-type="bibr" rid="RSOB200105C74">74</xref>], phenethyl isothiocyanate (PEITC) [<xref ref-type="bibr" rid="RSOB200105C75">75</xref>], <italic>tert</italic>-butylhydroquinone (tBHQ) [<xref ref-type="bibr" rid="RSOB200105C63">63</xref>–<xref ref-type="bibr" rid="RSOB200105C65">65</xref>,<xref ref-type="bibr" rid="RSOB200105C73">73</xref>], diethylmaleate (DEM) [<xref ref-type="bibr" rid="RSOB200105C65">65</xref>,<xref ref-type="bibr" rid="RSOB200105C73">73</xref>], dimethyl fumarate (DMF) [<xref ref-type="bibr" rid="RSOB200105C73">73</xref>,<xref ref-type="bibr" rid="RSOB200105C76">76</xref>], monoethyl fumarate (MEF) [<xref ref-type="bibr" rid="RSOB200105C76">76</xref>], hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) [<xref ref-type="bibr" rid="RSOB200105C67">67</xref>,<xref ref-type="bibr" rid="RSOB200105C77">77</xref>,<xref ref-type="bibr" rid="RSOB200105C78">78</xref>], hydrogen sulfide (H<sub>2</sub>S) [<xref ref-type="bibr" rid="RSOB200105C78">78</xref>], nitric oxide (NO) [<xref ref-type="bibr" rid="RSOB200105C64">64</xref>,<xref ref-type="bibr" rid="RSOB200105C67">67</xref>], nitro-oleic acid (OA-NO<sub>2</sub>) [<xref ref-type="bibr" rid="RSOB200105C63">63</xref>,<xref ref-type="bibr" rid="RSOB200105C65">65</xref>], (±)-S-nitroso-N-acetylpenicillamine (SNAP) [<xref ref-type="bibr" rid="RSOB200105C65">65</xref>], 4-hydroxy-2-nonenal (4-HNE) [<xref ref-type="bibr" rid="RSOB200105C65">65</xref>], 15-deoxy-Δ12,14-prostaglandin J<sub>2</sub> (15d-PGJ<sub>2</sub>) [<xref ref-type="bibr" rid="RSOB200105C65">65</xref>], prostaglandin A<sub>2</sub> (PGA<sub>2</sub>) [<xref ref-type="bibr" rid="RSOB200105C79">79</xref>], 8-nitroguanosine 3',5'-cyclic monophosphate (8-NO cGMP) [<xref ref-type="bibr" rid="RSOB200105C80">80</xref>], As<sup>3+</sup> [<xref ref-type="bibr" rid="RSOB200105C64">64</xref>,<xref ref-type="bibr" rid="RSOB200105C65">65</xref>], Cd<sup>2+</sup> [<xref ref-type="bibr" rid="RSOB200105C64">64</xref>], Zn<sup>2+</sup> [<xref ref-type="bibr" rid="RSOB200105C64">64</xref>,<xref ref-type="bibr" rid="RSOB200105C81">81</xref>], methylmercury (MeHg) [<xref ref-type="bibr" rid="RSOB200105C82">82</xref>], dexamethasone 21-mesylate (Dex-Mes) [<xref ref-type="bibr" rid="RSOB200105C61">61</xref>], 1,2-naphthoquinone (1,2-NQ) [<xref ref-type="bibr" rid="RSOB200105C79">79</xref>,<xref ref-type="bibr" rid="RSOB200105C83">83</xref>], 5-nitro-2-{[5-(phenoxymethyl)-4-phenyl-4H-1,2,4-triazol-3-yl]thio}pyridine (MIND4-17) [<xref ref-type="bibr" rid="RSOB200105C84">84</xref>], (Z)-ligustilide (Z-LIG) [<xref ref-type="bibr" rid="RSOB200105C85">85</xref>], oxidised-ligustilide (Ox-LIG) [<xref ref-type="bibr" rid="RSOB200105C85">85</xref>], diallyl trisulfide (DATS) [<xref ref-type="bibr" rid="RSOB200105C86">86</xref>], N-acetyl-p-benzoquinoneimine (NAPQI) [<xref ref-type="bibr" rid="RSOB200105C87">87</xref>], Se<sup>4+</sup> [<xref ref-type="bibr" rid="RSOB200105C64">64</xref>], acrolein [<xref ref-type="bibr" rid="RSOB200105C64">64</xref>], xanthohumol (XH) [<xref ref-type="bibr" rid="RSOB200105C88">88</xref>], 1-(4-hydroxy-3-methoxyphenyl)-4-tetradecen-3-one (10-shogaol) [<xref ref-type="bibr" rid="RSOB200105C88">88</xref>], iodoacetamide (IAA) [<xref ref-type="bibr" rid="RSOB200105C87">87</xref>], N-biotinylhexylenediamine (IAB) [<xref ref-type="bibr" rid="RSOB200105C89">89</xref>], 1-biotinamido-4-(4′-[maleimidoethyl-cyclohexane]-carboxamido) butane (BMCC) [<xref ref-type="bibr" rid="RSOB200105C89">89</xref>], isoliquiritigenin (ISO) [<xref ref-type="bibr" rid="RSOB200105C88">88</xref>], 2-phenyl-1,2-benzisoselenazol-3(2H)-one (Ebselen) [<xref ref-type="bibr" rid="RSOB200105C79">79</xref>,<xref ref-type="bibr" rid="RSOB200105C90">90</xref>], 4-octyl itaconate (4-OI) [<xref ref-type="bibr" rid="RSOB200105C45">45</xref>] and glutathione disulfide (GSSG) [<xref ref-type="bibr" rid="RSOB200105C91">91</xref>].</p></fn></table-wrap-foot></table-wrap></p>
<p>To date, there is no crystal structure of the intervening (IVR) domain of KEAP1 (aa 180 to 315) available. The KEAP1 IVR domain, flanked by the N-terminal BTB domain and the Kelch domain at the C-terminus, contains 8 cysteine residues (C196, C226, C241, C249, C257, C273, C288 and C297), of which, C273 and C288 are best characterized. Exposure to electrophiles or alkylating agents targeting the cysteines within the IVR domain, predominantly C273 and C288, leads to the inactivation of KEAP1 and subsequent activation of NRF2 [<xref ref-type="bibr" rid="RSOB200105C61">61</xref>,<xref ref-type="bibr" rid="RSOB200105C93">93</xref>,<xref ref-type="bibr" rid="RSOB200105C94">94</xref>]. Single or double mutations of C273 or C288 to serine or alanine render KEAP1 inactive with respect to its ability to repress and target for degradation NRF2 [<xref ref-type="bibr" rid="RSOB200105C63">63</xref>,<xref ref-type="bibr" rid="RSOB200105C64">64</xref>,<xref ref-type="bibr" rid="RSOB200105C93">93</xref>,<xref ref-type="bibr" rid="RSOB200105C95">95</xref>,<xref ref-type="bibr" rid="RSOB200105C96">96</xref>]. Since these C273S/A and C288S/A mutants inactivated KEAP1, they presented a difficulty to study the electrophiles that could potentially target these cysteines. By systematically mutating these cysteines, Saito and colleagues showed that single or double mutation of C273 and C288 to tryptophan or glutamic acid did not impede the KEAP1-mediated repression and degradation of NRF2 hence allowing to precisely identify electrophiles that are sensed by either or both of these cysteines [<xref ref-type="bibr" rid="RSOB200105C65">65</xref>]. In the report published by Saito <italic>et al</italic>. the authors showed that 15-deoxy-Δ<sup>12,14</sup>-prostaglandin J<sub>2</sub> (15d-PGJ<sub>2</sub>) is sensed specifically by C288, extending the earlier observations by Levonen <italic>et al</italic>. who recognized the importance of cysteine thiols within KEAP1 for sensing electrophilic lipids [<xref ref-type="bibr" rid="RSOB200105C95">95</xref>]. We performed molecular modelling of the amino acid residues comprising the IVR domain using the web-based I-TASSER platform service [<xref ref-type="bibr" rid="RSOB200105C97">97</xref>–<xref ref-type="bibr" rid="RSOB200105C99">99</xref>], and found that it is comprised of nine α-helices (<xref ref-type="fig" rid="RSOB200105F4">figure 4</xref>). The basic amino acids adjacent to C273 (i.e. R272 and H274) and C288 (i.e. K287) are expected to cause the deprotonation of the cysteine thiol groups, hence increasing their reactivity.
<fig id="RSOB200105F4" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Modelled structure of the human KEAP1 IVR domain. Cartoon representation of the I-TASSER program modelled human KEAP1 IVR domain displaying 9 α-helices (grey). The basic amino acids (ARG 272 and HIS 274, green) found adjacent to the CYS 273 residue (pink) as well as the hydrophobic LYS 287 (green) residue found adjacent to CYS 288 (pink) where their side chains are represented with stick drawings coloured by their respective elements. The structure was drawn with UCSF ChimeraX software.</p></caption><graphic xlink:href="rsob-10-200105-g4"></graphic></fig></p>
<p>The Kelch domain of KEAP1 is evolutionarily conserved and contains nine cysteine residues at amino acid positions 319, 368, 395, 406, 434, 489, 513, 518 and 583. The first crystal structure of the KEAP1 Kelch domain was solved at a resolution of 1.85Å in 2004 by Li and colleagues [<xref ref-type="bibr" rid="RSOB200105C100">100</xref>]. Several crystal structures of both the human and murine KEAP1 Kelch domains with different resolutions and in combination with compounds or short peptide sequences of the Neh2 domain of NRF2 have since been reported [<xref ref-type="bibr" rid="RSOB200105C101">101</xref>–<xref ref-type="bibr" rid="RSOB200105C107">107</xref>]. The Kelch domain in KEAP1 contains six Kelch repeats that assemble into a six-bladed β-propeller structure (blades I-VI), where the C-terminal residues form the first strand in the first blade (<xref ref-type="fig" rid="RSOB200105F1">figure 1</xref><italic>b</italic>). Four-stranded antiparallel β-sheets form one blade, where the shortest β-sheet is found at the central core [<xref ref-type="bibr" rid="RSOB200105C100">100</xref>,<xref ref-type="bibr" rid="RSOB200105C108">108</xref>]. The Kelch domain also contains double glycine repeats (DGR), which are located at the terminal end of the β-sheets.</p>
<p>First discovered in the laboratory of Masayuki Yamamoto in 1999 by Itoh and colleagues, the N-terminal Neh2 domain within NRF2 has been since reported by various groups to bind to the KEAP1 Kelch domain [<xref ref-type="bibr" rid="RSOB200105C56">56</xref>]. Using nuclear magnetic resonance spectroscopy, Tong <italic>et al</italic>. discovered that the Neh2 domain was intrinsically disordered [<xref ref-type="bibr" rid="RSOB200105C26">26</xref>]. It was subsequently found that the evolutionarily conserved DLG [<xref ref-type="bibr" rid="RSOB200105C109">109</xref>] and ETGE [<xref ref-type="bibr" rid="RSOB200105C56">56</xref>] motifs within the NRF2-Neh2 domain (<xref ref-type="fig" rid="RSOB200105F1">figure 1</xref><italic>a</italic>) were responsible for binding to the KEAP1 Kelch domains [<xref ref-type="bibr" rid="RSOB200105C26">26</xref>,<xref ref-type="bibr" rid="RSOB200105C110">110</xref>]. Compared with the ETGE motif, the DLG motif has a 200-fold lower affinity for the Kelch domain of KEAP1 [<xref ref-type="bibr" rid="RSOB200105C102">102</xref>]. The DLG and ETGE motifs flank a lysine-rich α-helix to allow for the conjugation of ubiquitin molecules by the activated ubiquitin conjugating E2 enzyme. Attachment of NRF2 to KEAP1 via both of these motifs is required for ubiquitination of the transcription factor, and a ‘fixed-ends’ or a ‘hinge-and-latch’ model for NRF2 ubiquitylation was proposed, where each binding motif of one molecule of NRF2 is tethered to a separate subunit of the KEAP1 homodimer [<xref ref-type="bibr" rid="RSOB200105C110">110</xref>,<xref ref-type="bibr" rid="RSOB200105C111">111</xref>]. Based on this knowledge, the Kelch domain of KEAP1 has become the target for the development of non-electrophilic NRF2 activators, which function as PPI inhibitors [<xref ref-type="bibr" rid="RSOB200105C112">112</xref>]. One example includes a series of 1,4-diphenyl-1,2,3-triazole compounds, which have been shown to disrupt the KEAP1:NRF2 PPIs <italic>in vitro</italic> using a fluorescence polarization assay, as well as in live cells expressing EGFP-NRF2 and KEAP1-mCherry fusion proteins using a Förster resonance energy transfer-based system and multiphoton fluorescence lifetime imaging microscopy [<xref ref-type="bibr" rid="RSOB200105C113">113</xref>].</p>
<p>The C-terminal domain of KEAP1 is the home of three of the four cysteine sensors of KEAP1, which are used redundantly to mediate NRF2 activation in response to hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), the major ROS in redox regulation of biological processes. Very recently, Suzuki <italic>et al</italic>. [<xref ref-type="bibr" rid="RSOB200105C77">77</xref>] generated a construct for mammalian cell expression of a KEAP1 mutant, which lacks 11 out of the 25 cysteine residues of the murine protein. This mutant KEAP1 was still able to target NRF2 for ubiquitination and proteasomal degradation, but was unable to respond to most cysteine-reactive NRF2 activators, including H<sub>2</sub>O<sub>2</sub>. A series of elegant experiments involving mouse embryonic fibroblast cells expressing various KEAP1 cysteine mutants as well as five distinct KEAP1 mutant mouse lines revealed that KEAP1 uses C226, C613, C622 and C624 redundantly to sense H<sub>2</sub>O<sub>2</sub> [<xref ref-type="bibr" rid="RSOB200105C77">77</xref>].</p>
<p>Although no crystal structure of full-length KEAP1 is available to date, a 24 Å resolution reconstituted electron microscopy (EM) structure has been described [<xref ref-type="bibr" rid="RSOB200105C114">114</xref>]. It shows that the KEAP1 dimer resembles a cherry-bob, where two large spheres, corresponding to the Kelch domains, are attached by short linker arms. Interestingly, each IVR domain surrounds the core of the Kelch domain, suggesting that chemical modifications of cysteines within the IVR domains may affect the KEAP1–NRF2 interactions through the Kelch domains.</p>
</sec>
<sec id="s3b">
<label>3.2.</label>
<title>KEAP1-CUL3 interaction</title>
<p>The primary system for protein degradation in the cell is the ubiquitin-proteasome system, where E3 ubiquitin ligases are essential components. Cullins are a family of hydrophobic proteins that confer substrate specificity by acting as scaffolds for E3 ubiquitin ligase complexes [<xref ref-type="bibr" rid="RSOB200105C115">115</xref>,<xref ref-type="bibr" rid="RSOB200105C116">116</xref>]. Thus far, in mammals, there have been seven Cullins (1, 2, 3, 4A, 4B, 5 and 7) identified. CUL3 is the only member of its family that is able to recognize BTB domains-containing proteins [<xref ref-type="bibr" rid="RSOB200105C116">116</xref>]. Since KEAP1 contains BTB domains, in 2004, Kobayashi and colleagues hypothesized that under basal conditions, CUL3 could be mediating the degradation of NRF2 through binding of the substrate adaptor KEAP1 [<xref ref-type="bibr" rid="RSOB200105C93">93</xref>]. Indeed, three independent groups simultaneously discovered that KEAP1 forms a functional E3 ubiquitin ligase complex with CUL3/RBX1 [<xref ref-type="bibr" rid="RSOB200105C93">93</xref>,<xref ref-type="bibr" rid="RSOB200105C117">117</xref>,<xref ref-type="bibr" rid="RSOB200105C118">118</xref>]. Shortly after, Furukawa &amp; Xiong reported that KEAP1 and CUL3 binding occurs between the BTB-domain of the former and the N-terminal domain of the latter [<xref ref-type="bibr" rid="RSOB200105C119">119</xref>]. Subsequently, it was discovered that CUL3 homodimerization requires the presence of its N-terminal domain and is dependent on its interaction with BTB domain-containing substrates (e.g. KEAP1) which also are able to homodimerize at their BTB domains [<xref ref-type="bibr" rid="RSOB200105C120">120</xref>].</p>
</sec>
</sec>
<sec id="s4">
<label>4.</label>
<title>The cyclic cyanoenones, the most potent class of NRF2 activators</title>
<p>To date, the cyanoenone triterpenoids are the most potent NRF2 activators known. They were designed and developed starting from the natural product oleanolic acid [<xref ref-type="bibr" rid="RSOB200105C121">121</xref>–<xref ref-type="bibr" rid="RSOB200105C123">123</xref>], and new generations of analogues have been synthesized [<xref ref-type="bibr" rid="RSOB200105C124">124</xref>]. These semi-synthetic compounds are highly electrophilic, bind covalently and reversibly to sulfhydryl groups [<xref ref-type="bibr" rid="RSOB200105C125">125</xref>], and have favourable pharmacokinetic and pharmacodynamic profiles <italic>in vivo,</italic> including in humans [<xref ref-type="bibr" rid="RSOB200105C126">126</xref>–<xref ref-type="bibr" rid="RSOB200105C128">128</xref>]. Currently, two cyanoenone triterpenoids are in clinical trials led by Reata Pharmaceuticals (USA) and Kyowa Hakko Kirin (Japan) for the treatment of diseases, which have been linked with chronic inflammation and abnormal redox homeostasis. One is CDDO-Me (2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid methyl ester; bardoxolone methyl, <xref ref-type="fig" rid="RSOB200105F5">figure 5</xref><italic>a</italic>) for the treatment of connective tissue disease–pulmonary arterial hypertension, pulmonary hypertension, Alport's syndrome, polycystic kidney disease, renal insufficiency and liver disease. The other is RTA-408 (omaveloxolone, <xref ref-type="fig" rid="RSOB200105F5">figure 5</xref><italic>b</italic>) for the treatment of Friedreich's ataxia, mitochondrial myopathy, ocular inflammation, ocular pain, corneal endothelial cell loss, cataract surgery, melanoma and radiation dermatitis in breast cancer patients [<xref ref-type="bibr" rid="RSOB200105C23">23</xref>]. Recently, Reata Pharmaceuticals reported the evaluation of the pharmacokinetics and tissue distribution of orally administered RTA-408 to cynomolgus monkeys after single and multiple oral doses, and the initial results from a clinical trial in Friedreich's ataxia patients [<xref ref-type="bibr" rid="RSOB200105C126">126</xref>]. Dose-dependent plasma levels of RTA-408 and induction of NRF2 target genes were detected in peripheral blood mononuclear cells, liver, lung, and brain of the animals. In patients, improvements in neurological functions were observed at doses of 80 mg or greater; these doses resulted in plasma drug concentrations consistent with those inducing NRF2 target genes in animals.
<fig id="RSOB200105F5" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Chemical structures of selected cyclic cyanoenone NRF2 activators.</p></caption><graphic xlink:href="rsob-10-200105-g5"></graphic></fig></p>
<p>To improve their potencies as anti-inflammatory agents and understand the details of their mechanism of action, numerous pentacyclic, tricyclic and monocyclic compounds containing cyanoenone functionalities were designed, synthesized and tested for their anti-inflammatory and NRF2-inducing activities in a programme of work led by Michael Sporn, Gordon Gribble, Tadashi Honda and Karen Liby at Dartmouth College [<xref ref-type="bibr" rid="RSOB200105C121">121</xref>,<xref ref-type="bibr" rid="RSOB200105C129">129</xref>–<xref ref-type="bibr" rid="RSOB200105C131">131</xref>]. In collaboration with the laboratory of Paul Talalay, these researchers found a linear correlation ranging over six orders of magnitude of concentrations between the potencies of 18 pentacyclic derivatives to inhibit inducible nitric oxide synthase (iNOS) and to activate the prototypic NRF2 target enzyme NQO1 [<xref ref-type="bibr" rid="RSOB200105C132">132</xref>]. Subsequently, this correlation was confirmed more broadly, for all main classes of NRF2 activators [<xref ref-type="bibr" rid="RSOB200105C133">133</xref>]. The high potency of the triterpenoid analogues in inducing NRF2 and inhibiting inflammation requires the presence of activated Michael reaction (enone) functions at critical positions in rings A and/or C. Among the cyclic cyanoenone derivatives, the acetylenic tricyclic bis(cyanoenone) TBE-31 is an exceptionally potent inducer (<xref ref-type="fig" rid="RSOB200105F5">figure 5</xref><italic>c</italic>). TBE-31 is active at sub- to low-nanomolar concentrations, with Concentration that Doubles the specific enzyme activity of NQO1 in murine Hepa1c1c7 cells (CD value) of 0.9 nM [<xref ref-type="bibr" rid="RSOB200105C134">134</xref>–<xref ref-type="bibr" rid="RSOB200105C137">137</xref>]. This compound is highly bioavailable and suitable for chronic oral administration [<xref ref-type="bibr" rid="RSOB200105C138">138</xref>,<xref ref-type="bibr" rid="RSOB200105C139">139</xref>]. The presence of two cyanoenone functionalities (in rings A and C) integrated in a three-ring structure confers particularly high inducer potency [<xref ref-type="bibr" rid="RSOB200105C138">138</xref>]. Another tricyclic cyanoenone, MCE-23 contains an identical ring C present in TBE-31, however, it does not have the cyanoenone moiety in its ring A (<xref ref-type="fig" rid="RSOB200105F5">figure 5</xref><italic>d</italic>), and is comparatively less potent, with a CD value of 41 nM [<xref ref-type="bibr" rid="RSOB200105C140">140</xref>]. MCE-1, a monocyclic cyanoenone (<xref ref-type="fig" rid="RSOB200105F5">figure 5</xref><italic>e</italic>), contains the ring C of MCE-23 and TBE-31. Similar to MCE-23 and TBE-31, MCE-1 also induces NQO1 (CD = 22 nM) [<xref ref-type="bibr" rid="RSOB200105C131">131</xref>,<xref ref-type="bibr" rid="RSOB200105C138">138</xref>]. All of these cyanoenones exhibit anti-inflammatory activity in RAW 264.7 cells as well as primary macrophage (PM<italic>Φ</italic>) cells derived from mice [<xref ref-type="bibr" rid="RSOB200105C131">131</xref>,<xref ref-type="bibr" rid="RSOB200105C138">138</xref>]. Furthermore, in a murine inflammation-mediated depression model, MCE-1 and TBE-31 exhibit anti-depressant effects [<xref ref-type="bibr" rid="RSOB200105C141">141</xref>].</p>
<p>CDDO-Me, RTA-408, MCE-1, MCE-23 and TBE-31 possess electrophilic Michael acceptor(s) within their chemical structures, and are therefore extremely reactive with sulfhydryl groups. Early studies employing ultraviolet–visible (UV-VIS) spectroscopy had shown that compounds of this class react with cysteines in KEAP1, but the identity of the specific cysteine sensor(s) within the protein was not known [<xref ref-type="bibr" rid="RSOB200105C132">132</xref>,<xref ref-type="bibr" rid="RSOB200105C136">136</xref>]. In collaboration with Takafumi Suzuki and Masayuki Yamamoto (Tohoku University), we generated KEAP1-knockout mouse embryonic fibroblast (MEF) cells that were reinstated with wild-type or various cysteine mutants of KEAP1, and monitored the stabilization of NRF2 upon exposure to cyanoenones [<xref ref-type="bibr" rid="RSOB200105C70">70</xref>]. In addition, we isolated PM<italic>Φ</italic> cells from wild-type KEAP1 (KEAP<sup>+/+</sup>) or the knock-in mutant KEAP-C151S (KEAP<sup>C151S/C151S</sup>) mice, which were generated by use of the CRISPR/Cas9 technology. This study revealed that C151 is the primary sensor for the cyanoenone class of NRF2 inducers, irrespective of their molecular shape or size. Furthermore, C151S mutation in KEAP1 (i.e. in the KEAP1<sup>C151S/C151S</sup> PM<italic>Φ</italic> cells) not only abolished the inducer activity of low concentrations of TBE-31, but it also diminished its anti-inflammatory activity. This effect was confirmed using transgenic mice expressing human interleukin 6 (IL-6)-luciferase reporter that were either KEAP1 wild-type or KEAP<sup>C151S/C151S</sup> mutant. Taken together, these experiments highlight the anti-inflammatory effect of NRF2 activation.</p>
<p>It is noteworthy that, although C151 is the primary sensor for the cyanoenone class of NRF2 inducers, the concentration of the inducer is critical for on-target selectivity. Thus, at low cyanoenone concentrations, C151 is essential for NRF2 stabilization, however, at higher cyanoenone concentrations, NRF2 stabilization proceeds in the absence of C151 [<xref ref-type="bibr" rid="RSOB200105C70">70</xref>]. These findings underscore the importance of the inherent flexibility of the sensor cysteines in KEAP1, explain the apparent discrepancies between the results from some of the published studies, and highlight the immense importance of determining the accurate dose of even the most selective electrophilic NRF2 inducer for achieving on-target selectivity.</p>
<p>Because RTA-408 can cross the blood–brain barrier and is currently in clinical development [<xref ref-type="bibr" rid="RSOB200105C23">23</xref>], its disease-modifying efficacy was tested in a rat model of status epilepticus, a disease, where cytotoxicity and inflammation constitute major pathogenic drivers. In a study led by Matthew Walker, Andrey Abramov and their colleagues at University College London, it was found that 3 daily doses of RTA-408 given in the first week of established disease potently inhibited epileptogenesis during the subsequent 12 weeks, and preserved both neurons and astrocytes in the hippocampus of the animals [<xref ref-type="bibr" rid="RSOB200105C71">71</xref>]. This remarkable effect indicates that breaking the vicious circle of redox imbalance causing macromolecular damage and cell death triggering inflammation leading to neuronal death and seizures, which in turn cause more neuronal death and greater inflammation, and more seizures, can be highly effective in managing this disease. Most importantly, the unprecedented high efficacy of RTA-408 in this model, and the fact that it is currently in clinical trials, suggests the potential for this drug as a disease-modifying treatment in epilepsy and perhaps other neurological conditions.</p>
</sec>
<sec id="s5">
<label>5.</label>
<title>Concluding remarks</title>
<p>The extraordinary ability of KEAP1 to sense a multitude of inducers that vary in shape, size and reactivity, and are able to ‘read’ an intricately complex ‘cysteine code’, coupled with its intrinsic flexibility, guarantees a finely tuned, and tightly regulated antioxidant response. More than two decades of research conducted by numerous independent groups of investigators has convincingly demonstrated that the ability to mount this cytoprotective response is critical for adaptation and survival, and can be exploited to protect against or delay the onset of pathological processes, particularly those that involve oxidative stress and inflammation. Indeed, KEAP1 is the target of several small-molecule NRF2 activators, which are currently in clinical trials and hold promise for the prevention and treatment of chronic disease.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="d38e141">
<caption>
<title>Reviewer comments</title>
</caption>
<media mime-subtype="pdf" mimetype="application" xlink:href="rsob200105_review_history.pdf"></media>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>We are immensely grateful to Michael Sporn, Gordon Gribble, Tadashi Honda and Karen Liby (Dartmouth College, USA) for introducing us to the cyanoenone class of NRF2 activators and most enjoyable collaborative interactions.</p>
</ack>
<sec id="s6">
<title>Data accessibility</title>
<p>This article has no additional data.</p>
</sec>
<sec id="s7" sec-type="COI-statement">
<title>Competing interests</title>
<p>A.T.D-K. is a member of the Scientific Advisory Board of Evgen Pharma and a consultant for Aclipse Therapeutics and Vividion Therapeutics.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>We thank Cancer Research UK (C20953/A18644) and Reata Pharmaceuticals for financial support.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="RSOB200105C1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sies</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>DP</given-names></name></person-group>
<comment>In press.</comment>
<article-title>Reactive oxygen species (ROS) as pleiotropic physiological signalling agents</article-title>. <source/>Nat. Rev. Mol. Cell Biol. (<pub-id pub-id-type="doi">10.1038/s41580-020-0230-3</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sies</surname><given-names>H</given-names></name></person-group>
<year>2015</year>
<article-title>Oxidative stress: a concept in redox biology and medicine</article-title>. <source/>Redox Biol.
<volume>4</volume>, <fpage>180</fpage>–<lpage>183</lpage>. (<pub-id pub-id-type="doi">10.1016/j.redox.2015.01.002</pub-id>)<pub-id pub-id-type="pmid">25588755</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>JK</given-names></name></person-group>
<year>2004</year>
<article-title>Oxidative stress in neurodegeneration: cause or consequence?</article-title>
<source/>Nat. Med.
<volume>10</volume>, <fpage>S18</fpage>-<lpage>S25</lpage>. (<pub-id pub-id-type="doi">10.1038/nrn1434</pub-id>)<pub-id pub-id-type="pmid">15298006</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukui</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Moraes</surname><given-names>CT</given-names></name></person-group>
<year>2008</year>
<article-title>The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis?</article-title>
<source/>Trends Neurosci.
<volume>31</volume>, <fpage>251</fpage>–<lpage>256</lpage>. (<pub-id pub-id-type="doi">10.1016/j.tins.2008.02.008</pub-id>)<pub-id pub-id-type="pmid">18403030</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahalingaiah</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Ponnusamy</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>KP</given-names></name></person-group>
<year>2015</year>
<article-title>Chronic oxidative stress causes estrogen-independent aggressive phenotype, and epigenetic inactivation of estrogen receptor alpha in MCF-7 breast cancer cells</article-title>. <source/>Breast Cancer Res. Treat.
<volume>153</volume>, <fpage>41</fpage>–<lpage>56</lpage>. (<pub-id pub-id-type="doi">10.1007/s10549-015-3514-0</pub-id>)<pub-id pub-id-type="pmid">26208486</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehlman</surname><given-names>MA</given-names></name></person-group>
<year>1992</year>
<article-title>Dangerous and cancer-causing properties of products and chemicals in the oil refining and petrochemical industry. VIII. Health effects of motor fuels: carcinogenicity of gasoline--scientific update</article-title>. <source/>Environ. Res.
<volume>59</volume>, <fpage>238</fpage>–<lpage>249</lpage>. (<pub-id pub-id-type="doi">10.1016/S0013-9351(05)80243-9</pub-id>)<pub-id pub-id-type="pmid">1425514</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceriello</surname><given-names>A</given-names></name></person-group>
<year>2006</year>
<article-title>Oxidative stress and diabetes-associated complications</article-title>. <source/>Endocr Pract.
<volume>12</volume>(<issue>Suppl. 1</issue>), <fpage>60</fpage>–<lpage>62</lpage>. (<pub-id pub-id-type="doi">10.4158/EP.12.S1.60</pub-id>)<pub-id pub-id-type="pmid">16627383</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bravi</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Armiento</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Laurenti</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Cassone-Faldetta</surname><given-names>M</given-names></name>, <name name-style="western"><surname>De Luca</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Moretti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>De Mattia</surname><given-names>G.</given-names></name></person-group>
<year>2006</year>
<article-title>Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus</article-title>. <source/>Metabolism
<volume>55</volume>, <fpage>691</fpage>–<lpage>695</lpage>. (<pub-id pub-id-type="doi">10.1016/j.metabol.2006.01.003</pub-id>)<pub-id pub-id-type="pmid">16631447</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pathak</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dalal</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Paul</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Biswas</surname><given-names>S</given-names></name></person-group>
<comment>In press.</comment>
<article-title>Oxidative stress in autoimmune diseases: an under dealt malice</article-title>. <source/>Curr. Protein Pept Sci. (<pub-id pub-id-type="doi">10.2174/1389203721666200214111816</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C10">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rinnerthaler</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bischof</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Streubel</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Trost</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Richter</surname><given-names>K</given-names></name></person-group>
<year>2015</year>
<article-title>Oxidative stress in aging human skin</article-title>. <source/>Biomolecules
<volume>5</volume>, <fpage>545</fpage>–<lpage>589</lpage>. (<pub-id pub-id-type="doi">10.3390/biom5020545</pub-id>)<pub-id pub-id-type="pmid">25906193</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruk</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Duchnik</surname><given-names>E</given-names></name></person-group>
<year>2014</year>
<article-title>Oxidative stress and skin diseases: possible role of physical activity</article-title>. <source/>Asian Pac. J. Cancer Prev.
<volume>15</volume>, <fpage>561</fpage>–<lpage>568</lpage>. (<pub-id pub-id-type="doi">10.7314/apjcp.2014.15.2.561</pub-id>)<pub-id pub-id-type="pmid">24568458</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okayama</surname><given-names>Y</given-names></name></person-group>
<year>2005</year>
<article-title>Oxidative stress in allergic and inflammatory skin diseases</article-title>. <source/>Curr. Drug Targets Inflamm. Allergy
<volume>4</volume>, <fpage>517</fpage>–<lpage>519</lpage>. (<pub-id pub-id-type="doi">10.2174/1568010054526386</pub-id>)<pub-id pub-id-type="pmid">16127829</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hector</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Griese</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hartl</surname><given-names>D</given-names></name></person-group>
<year>2014</year>
<article-title>Oxidative stress in cystic fibrosis lung disease: an early event, but worth targeting?</article-title>
<source/>Eur. Respir. J.
<volume>44</volume>, <fpage>17</fpage>–<lpage>19</lpage>. (<pub-id pub-id-type="doi">10.1183/09031936.00038114</pub-id>)<pub-id pub-id-type="pmid">24982050</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bast</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Weseler</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Haenen</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>den Hartog</surname><given-names>GJ</given-names></name></person-group>
<year>2010</year>
<article-title>Oxidative stress and antioxidants in interstitial lung disease</article-title>. <source/>Curr. Opin Pulm. Med.
<volume>16</volume>, <fpage>516</fpage>–<lpage>520</lpage>. (<pub-id pub-id-type="doi">10.1097/MCP.0b013e32833c645d</pub-id>)<pub-id pub-id-type="pmid">20592594</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Reina-Couto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Albino-Teixeira</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sousa</surname><given-names>T</given-names></name></person-group>
<year>2016</year>
<article-title>Statins and oxidative stress in chronic heart failure</article-title>. <source/>Rev. Port. Cardiol.
<volume>35</volume>, <fpage>41</fpage>–<lpage>57</lpage>. (<pub-id pub-id-type="doi">10.1016/j.repc.2015.09.006</pub-id>)<pub-id pub-id-type="pmid">26763895</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Bartosch</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Isaguliants</surname><given-names>MG</given-names></name></person-group>
<year>2017</year>
<article-title>Oxidative stress in infection and consequent disease</article-title>. <source/>Oxid. Med. Cell Longev.
<volume>2017</volume>, <fpage>3496043</fpage> (<pub-id pub-id-type="doi">10.1155/2017/3496043</pub-id>)<pub-id pub-id-type="pmid">28255425</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muntane</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Puig-Parellada</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mitjavila</surname><given-names>MT</given-names></name></person-group>
<year>1995</year>
<article-title>Iron metabolism and oxidative stress during acute and chronic phases of experimental inflammation: effect of iron-dextran and deferoxamine</article-title>. <source/>J. Lab. Clin. Med.
<volume>126</volume>, <fpage>435</fpage>–<lpage>443</lpage>.<pub-id pub-id-type="pmid">7595028</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liguori</surname><given-names>I</given-names></name></person-group>
<italic>et al.</italic>
<year>2018</year>
<article-title>Oxidative stress, aging, and diseases</article-title>. <source/>Clin. Interv. Aging.
<volume>13</volume>, <fpage>757</fpage>–<lpage>772</lpage>. (<pub-id pub-id-type="doi">10.2147/CIA.S158513</pub-id>)<pub-id pub-id-type="pmid">29731617</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukagawa</surname><given-names>NK</given-names></name></person-group>
<year>1999</year>
<article-title>Aging: is oxidative stress a marker or is it causal?</article-title>
<source/>Proc. Soc. Exp. Biol. Med.
<volume>222</volume>, <fpage>293</fpage>–<lpage>298</lpage>. (<pub-id pub-id-type="doi">10.1046/j.1525-1373.1999.d01-146.x</pub-id>)<pub-id pub-id-type="pmid">10601888</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Roth</surname><given-names>GS</given-names></name></person-group>
<year>1992</year>
<article-title>Cholinergic systems in aging: the role of oxidative stress</article-title>. <source/>Clin. Neuropharmacol.
<volume>15(</volume><issue>Suppl 1 Pt A</issue>), <fpage>508A</fpage>-<lpage>509A</lpage>. (<pub-id pub-id-type="doi">10.1097/00002826-199201001-00264</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayes</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name></person-group>
<year>2014</year>
<article-title>The Nrf2 regulatory network provides an interface between redox and intermediary metabolism</article-title>. <source/>Trends Biochem. Sci.
<volume>39</volume>, <fpage>199</fpage>–<lpage>218</lpage>. (<pub-id pub-id-type="doi">10.1016/j.tibs.2014.02.002</pub-id>)<pub-id pub-id-type="pmid">24647116</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Kostov</surname><given-names>RV</given-names></name>, <name name-style="western"><surname>Canning</surname><given-names>P</given-names></name></person-group>
<year>2017</year>
<article-title>Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants</article-title>. <source/>Arch. Biochem. Biophys.
<volume>617</volume>, <fpage>84</fpage>–<lpage>93</lpage>. (<pub-id pub-id-type="doi">10.1016/j.abb.2016.08.005</pub-id>)<pub-id pub-id-type="pmid">27497696</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuadrado</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2019</year>
<article-title>Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases</article-title>. <source/>Nat. Rev. Drug Discov.
<volume>18</volume>, <fpage>295</fpage>–<lpage>317</lpage>. (<pub-id pub-id-type="doi">10.1038/s41573-018-0008-x</pub-id>)<pub-id pub-id-type="pmid">30610225</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lleres</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Swift</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name></person-group>
<year>2013</year>
<article-title>Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>110</volume>, <fpage>15 259</fpage>–<lpage>15 264</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.1305687110</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name></person-group>
<year>2013</year>
<article-title>Diffusion dynamics of the Keap1-Cullin3 interaction in single live cells</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>433</volume>, <fpage>58</fpage>–<lpage>65</lpage>. (<pub-id pub-id-type="doi">10.1016/j.bbrc.2013.02.065</pub-id>)<pub-id pub-id-type="pmid">23454126</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>KI</given-names></name>, <name name-style="western"><surname>Katoh</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kusunoki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Itoh</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tanaka</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name></person-group>
<year>2006</year>
<article-title>Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model</article-title>. <source/>Mol. Cell Biol.
<volume>26</volume>, <fpage>2887</fpage>–<lpage>2900</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.26.8.2887-2900.2006</pub-id>)<pub-id pub-id-type="pmid">16581765</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dodson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>de la Vega</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Cholanians</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Schmidlin</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Chapman</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>DD.</given-names></name></person-group>
<year>2019</year>
<article-title>Modulating NRF2 in disease: timing is everything</article-title>. <source/>Annu. Rev. Pharmacol. Toxicol.
<volume>59</volume>, <fpage>555</fpage>–<lpage>575</lpage>. (<pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010818-021856</pub-id>)<pub-id pub-id-type="pmid">30256716</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C28">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tonelli</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chio</surname><given-names>C.</given-names><suffix>II</suffix></name>, <name name-style="western"><surname>Tuveson</surname><given-names>DA</given-names></name></person-group>
<year>2018</year>
<article-title>Transcriptional regulation by Nrf2</article-title>. <source/>Antioxid Redox Signal.
<volume>29</volume>, <fpage>1727</fpage>–<lpage>1745</lpage>. (<pub-id pub-id-type="doi">10.1089/ars.2017.7342</pub-id>)<pub-id pub-id-type="pmid">28899199</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>SC</given-names></name></person-group>
<year>2009</year>
<article-title>Regulation of glutathione synthesis</article-title>. <source/>Mol. Aspects Med.
<volume>30</volume>, <fpage>42</fpage>–<lpage>59</lpage>. (<pub-id pub-id-type="doi">10.1016/j.mam.2008.05.005</pub-id>)<pub-id pub-id-type="pmid">18601945</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teskey</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Glutathione as a marker for human disease</article-title>. <source/>Adv. Clin. Chem.
<volume>87</volume>, <fpage>141</fpage>–<lpage>159</lpage>. (<pub-id pub-id-type="doi">10.1016/bs.acc.2018.07.004</pub-id>)<pub-id pub-id-type="pmid">30342710</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>YZ</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lupton</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>ND</given-names></name></person-group>
<year>2004</year>
<article-title>Glutathione metabolism and its implications for health</article-title>. <source/>J. Nutr.
<volume>134</volume>, <fpage>489</fpage>–<lpage>492</lpage>. (<pub-id pub-id-type="doi">10.1093/jn/134.3.489</pub-id>)<pub-id pub-id-type="pmid">14988435</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wild</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Mulcahy</surname><given-names>RT</given-names></name></person-group>
<year>2000</year>
<article-title>Regulation of gamma-glutamylcysteine synthetase subunit gene expression: insights into transcriptional control of antioxidant defenses</article-title>. <source/>Free Radic. Res.
<volume>32</volume>, <fpage>281</fpage>–<lpage>301</lpage>. (<pub-id pub-id-type="doi">10.1080/10715760000300291</pub-id>)<pub-id pub-id-type="pmid">10741850</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaki</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<year>2002</year>
<article-title>Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression</article-title>. <source/>J. Biol. Chem.
<volume>277</volume>, <fpage>44 765</fpage>–<lpage>44 771</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M208704200</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitsuishi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Taguchi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kawatani</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shibata</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nukiwa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Aburatani</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Motohashi</surname><given-names>H</given-names></name></person-group>
<year>2012</year>
<article-title>Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming</article-title>. <source/>Cancer Cell
<volume>22</volume>, <fpage>66</fpage>–<lpage>79</lpage>. (<pub-id pub-id-type="doi">10.1016/j.ccr.2012.05.016</pub-id>)<pub-id pub-id-type="pmid">22789539</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirotsu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Katsuoka</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Funayama</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nagashima</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nishida</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Nakayama</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Engel</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name></person-group>
<year>2012</year>
<article-title>Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks</article-title>. <source/>Nucleic Acids Res.
<volume>40</volume>, <fpage>10 228</fpage>–<lpage>10 239</lpage>. (<pub-id pub-id-type="doi">10.1093/nar/gks827</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis</article-title>. <source/>J. Clin. Invest.
<volume>123</volume>, <fpage>2921</fpage>–<lpage>2934</lpage>. (<pub-id pub-id-type="doi">10.1172/JCI66353</pub-id>)<pub-id pub-id-type="pmid">23921124</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vargas</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Sirkis</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Messing</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>JA</given-names></name></person-group>
<year>2008</year>
<article-title>Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis</article-title>. <source/>J. Neurosci.
<volume>28</volume>, <fpage>13 574</fpage>–<lpage>13 581</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4099-08.2008</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuadrado</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Moreno-Murciano</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pedraza-Chaverri</surname><given-names>J</given-names></name></person-group>
<year>2009</year>
<article-title>The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease</article-title>. <source/>Expert Opin. Ther. Targets.
<volume>13</volume>, <fpage>319</fpage>–<lpage>329</lpage>. (<pub-id pub-id-type="doi">10.1517/13543780802716501</pub-id>)<pub-id pub-id-type="pmid">19236154</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schousboe</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Scafidi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bak</surname><given-names>LK</given-names></name>, <name name-style="western"><surname>Waagepetersen</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>McKenna</surname><given-names>MC</given-names></name></person-group>
<year>2014</year>
<article-title>Glutamate metabolism in the brain focusing on astrocytes</article-title>. <source/>Adv. Neurobiol.
<volume>11</volume>, <fpage>13</fpage>–<lpage>30</lpage>. (<pub-id pub-id-type="doi">10.1007/978-3-319-08894-5_2</pub-id>)<pub-id pub-id-type="pmid">25236722</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>KF</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2</article-title>. <source/>Nat. Commun.
<volume>6</volume>, <fpage>7066</fpage> (<pub-id pub-id-type="doi">10.1038/ncomms8066</pub-id>)<pub-id pub-id-type="pmid">25967870</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Vargas</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Pani</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Smeyne</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Kan</surname><given-names>YW</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>JA</given-names></name></person-group>
<year>2009</year>
<article-title>Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>106</volume>, <fpage>2933</fpage>–<lpage>2938</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0813361106</pub-id>)<pub-id pub-id-type="pmid">19196989</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayin</surname><given-names>VI</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer</article-title>. <source/>Elife
<volume>6</volume>, <fpage>e28083</fpage> (<pub-id pub-id-type="doi">10.7554/eLife.28083</pub-id>)<pub-id pub-id-type="pmid">28967864</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zimmerman</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Connors</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Diggins</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Stephenson</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Fahey</surname><given-names>JW</given-names></name></person-group>
<year>2020</year>
<article-title>Biomarker exploration in human peripheral blood mononuclear cells for monitoring sulforaphane treatment responses in autism spectrum disorder</article-title>. <source/>Sci. Rep.
<volume>10</volume>, <fpage>5822</fpage> (<pub-id pub-id-type="doi">10.1038/s41598-020-62714-4</pub-id>)<pub-id pub-id-type="pmid">32242086</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bambouskova</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Electrophilic properties of itaconate and derivatives regulate the IkappaBzeta-ATF3 inflammatory axis</article-title>. <source/>Nature
<volume>556</volume>, <fpage>501</fpage>–<lpage>504</lpage>. (<pub-id pub-id-type="doi">10.1038/s41586-018-0052-z</pub-id>)<pub-id pub-id-type="pmid">29670287</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>EL</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1</article-title>. <source/>Nature
<volume>556</volume>, <fpage>113</fpage>–<lpage>117</lpage>. (<pub-id pub-id-type="doi">10.1038/nature25986</pub-id>)<pub-id pub-id-type="pmid">29590092</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>EH</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription</article-title>. <source/>Nat. Commun.
<volume>7</volume>, <fpage>11624</fpage> (<pub-id pub-id-type="doi">10.1038/ncomms11624</pub-id>)<pub-id pub-id-type="pmid">27211851</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C47">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Thimmulappa</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Craciun</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Harvey</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kombairaju</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Remick</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Biswal</surname><given-names>S</given-names></name></person-group>
<year>2011</year>
<article-title>Enhancing Nrf2 pathway by disruption of Keap1 in myeloid leukocytes protects against sepsis</article-title>. <source/>Am. J. Respir. Crit. Care Med.
<volume>184</volume>, <fpage>928</fpage>–<lpage>938</lpage>. (<pub-id pub-id-type="doi">10.1164/rccm.201102-0271OC</pub-id>)<pub-id pub-id-type="pmid">21799073</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olagnier</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Activation of Nrf2 signaling augments vesicular stomatitis virus oncolysis via autophagy-driven suppression of antiviral immunity</article-title>. <source/>Mol. Ther.
<volume>25</volume>, <fpage>1900</fpage>–<lpage>1916</lpage>. (<pub-id pub-id-type="doi">10.1016/j.ymthe.2017.04.022</pub-id>)<pub-id pub-id-type="pmid">28527723</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thimmulappa</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Rangasamy</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kensler</surname><given-names>TW</given-names></name>, <name name-style="western"><surname>Biswal</surname><given-names>S</given-names></name></person-group>
<year>2006</year>
<article-title>Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis</article-title>. <source/>J. Clin. Invest.
<volume>116</volume>, <fpage>984</fpage>–<lpage>995</lpage>. (<pub-id pub-id-type="doi">10.1172/JCI25790</pub-id>)<pub-id pub-id-type="pmid">16585964</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baardman</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<year>2018</year>
<article-title>A defective pentose phosphate pathway reduces inflammatory macrophage responses during hypercholesterolemia</article-title>. <source/>Cell Rep.
<volume>25</volume>, <fpage>2044</fpage>–<lpage>2052</lpage>. (<pub-id pub-id-type="doi">10.1016/j.celrep.2018.10.092</pub-id>)<pub-id pub-id-type="pmid">30463003</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuadrado</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach</article-title>. <source/>Pharmacol. Rev.
<volume>70</volume>, <fpage>348</fpage>–<lpage>383</lpage>. (<pub-id pub-id-type="doi">10.1124/pr.117.014753</pub-id>)<pub-id pub-id-type="pmid">29507103</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sporn</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Liby</surname><given-names>KT</given-names></name></person-group>
<year>2012</year>
<article-title>NRF2 and cancer: the good, the bad and the importance of context</article-title>. <source/>Nat. Rev. Cancer.
<volume>12</volume>, <fpage>564</fpage>–<lpage>571</lpage>. (<pub-id pub-id-type="doi">10.1038/nrc3278</pub-id>)<pub-id pub-id-type="pmid">22810811</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robledinos-Anton</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Fernandez-Gines</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Manda</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cuadrado</surname><given-names>A</given-names></name></person-group>
<year>2019</year>
<article-title>Activators and inhibitors of NRF2: a review of their potential for clinical development</article-title>. <source/>Oxid. Med. Cell. Longev.
<volume>2019</volume>, <fpage>9372182</fpage> (<pub-id pub-id-type="doi">10.1155/2019/9372182</pub-id>)<pub-id pub-id-type="pmid">31396308</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prochaska</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>De Long</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Talalay</surname><given-names>P.</given-names></name></person-group>
<year>1985</year>
<article-title>On the mechanisms of induction of cancer-protective enzymes: a unifying proposal</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>82</volume>, <fpage>8232</fpage>–<lpage>8236</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.82.23.8232</pub-id>)<pub-id pub-id-type="pmid">3934671</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talalay</surname><given-names>P</given-names></name>, <name name-style="western"><surname>De Long</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Prochaska</surname><given-names>HJ.</given-names></name></person-group>
<year>1988</year>
<article-title>Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>85</volume>, <fpage>8261</fpage>–<lpage>8265</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.85.21.8261</pub-id>)<pub-id pub-id-type="pmid">3141925</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itoh</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wakabayashi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Katoh</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ishii</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Igarashi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Engel</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name></person-group>
<year>1999</year>
<article-title>Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain</article-title>. <source/>Genes Dev.
<volume>13</volume>, <fpage>76</fpage>–<lpage>86</lpage>. (<pub-id pub-id-type="doi">10.1101/gad.13.1.76</pub-id>)<pub-id pub-id-type="pmid">9887101</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marino</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Gladyshev</surname><given-names>VN</given-names></name></person-group>
<year>2012</year>
<article-title>Analysis and functional prediction of reactive cysteine residues</article-title>. <source/>J. Biol. Chem.
<volume>287</volume>, <fpage>4419</fpage>–<lpage>4425</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.R111.275578</pub-id>)<pub-id pub-id-type="pmid">22157013</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C58">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roos</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Foloppe</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Messens</surname><given-names>J</given-names></name></person-group>
<year>2013</year>
<article-title>Understanding the pK(a) of redox cysteines: the key role of hydrogen bonding</article-title>. <source/>Antioxid Redox Signal.
<volume>18</volume>, <fpage>94</fpage>–<lpage>127</lpage>. (<pub-id pub-id-type="doi">10.1089/ars.2012.4521</pub-id>)<pub-id pub-id-type="pmid">22746677</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gould</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Martinez-Acedo</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Marino</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Gladyshev</surname><given-names>VN</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Ischiropoulos</surname><given-names>H</given-names></name></person-group>
<year>2015</year>
<article-title>Site-specific proteomic mapping identifies selectively modified regulatory cysteine residues in functionally distinct protein networks</article-title>. <source/>Chem. Biol.
<volume>22</volume>, <fpage>965</fpage>–<lpage>975</lpage>. (<pub-id pub-id-type="doi">10.1016/j.chembiol.2015.06.010</pub-id>)<pub-id pub-id-type="pmid">26165157</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snyder</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Cennerazzo</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Karalis</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Field</surname><given-names>D</given-names></name></person-group>
<year>1981</year>
<article-title>Electrostatic influence of local cysteine environments on disulfide exchange kinetics</article-title>. <source/>Biochemistry
<volume>20</volume>, <fpage>6509</fpage>–<lpage>6519</lpage>. (<pub-id pub-id-type="doi">10.1021/bi00526a001</pub-id>)<pub-id pub-id-type="pmid">6796114</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C61">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Holtzclaw</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Cole</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Itoh</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wakabayashi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Katoh</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Talalay</surname><given-names>P</given-names></name></person-group>
<year>2002</year>
<article-title>Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>99</volume>, <fpage>11 908</fpage>–<lpage>11 913</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.172398899</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C62">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zipper</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Mulcahy</surname><given-names>RT</given-names></name></person-group>
<year>2002</year>
<article-title>The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm</article-title>. <source/>J. Biol. Chem.
<volume>277</volume>, <fpage>36 544</fpage>–<lpage>36 552</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M206530200</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C63">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Hannink</surname><given-names>M</given-names></name></person-group>
<year>2003</year>
<article-title>Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress</article-title>. <source/>Mol. Cell. Biol.
<volume>23</volume>, <fpage>8137</fpage>–<lpage>8151</lpage>. (<pub-id pub-id-type="doi">10.1128/mcb.23.22.8137-8151.2003</pub-id>)<pub-id pub-id-type="pmid">14585973</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C64">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMahon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lamont</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Beattie</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Hayes</surname><given-names>JD</given-names></name></person-group>
<year>2010</year>
<article-title>Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals</article-title>. <source/>Proc. Natl Acad. Sci. USA.
<volume>107</volume>, <fpage>18 838</fpage>–<lpage>18 843</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.1007387107</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C65">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Characterizations of three major cysteine sensors of keap1 in stress response</article-title>. <source/>Mol. Cell Biol.
<volume>36</volume>, <fpage>271</fpage>–<lpage>284</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.00868-15</pub-id>)<pub-id pub-id-type="pmid">26527616</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C66">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Habib</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Lieberman</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Hannink</surname><given-names>M</given-names></name></person-group>
<year>2005</year>
<article-title>Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway</article-title>. <source/>J. Biol. Chem.
<volume>280</volume>, <fpage>30 091</fpage>–<lpage>30 099</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M501279200</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C67">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fourquet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Guerois</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Biard</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Toledano</surname><given-names>MB</given-names></name></person-group>
<year>2010</year>
<article-title>Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>8463</fpage>–<lpage>8471</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M109.051714</pub-id>)<pub-id pub-id-type="pmid">20061377</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C68">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bollong</surname><given-names>MJ</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling</article-title>. <source/>Nature
<volume>562</volume>, <fpage>600</fpage>–<lpage>604</lpage>. (<pub-id pub-id-type="doi">10.1038/s41586-018-0622-0</pub-id>)<pub-id pub-id-type="pmid">30323285</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C69">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation</article-title>. <source/>Biochem. J.
<volume>443</volume>, <fpage>213</fpage>–<lpage>222</lpage>. (<pub-id pub-id-type="doi">10.1042/BJ20111648</pub-id>)<pub-id pub-id-type="pmid">22188542</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C70">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dayalan Naidu</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape</article-title>. <source/>Sci. Rep.
<volume>8</volume>, <fpage>8037</fpage> (<pub-id pub-id-type="doi">10.1038/s41598-018-26269-9</pub-id>)<pub-id pub-id-type="pmid">29795117</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C71">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shekh-Ahmad</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Eckel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dayalan Naidu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Higgins</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Kovac</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Abramov</surname><given-names>AY</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>MC</given-names></name></person-group>
<year>2018</year>
<article-title>KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy</article-title>. <source/>Brain
<volume>141</volume>, <fpage>1390</fpage>–<lpage>1403</lpage>. (<pub-id pub-id-type="doi">10.1093/brain/awy071</pub-id>)<pub-id pub-id-type="pmid">29538645</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C72">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cleasby</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO</article-title>. <source/>PLoS ONE
<volume>9</volume>, <fpage>e98896</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0098896</pub-id>)<pub-id pub-id-type="pmid">24896564</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C73">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takaya</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Motohashi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Onodera</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Satomi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kensler</surname><given-names>TW</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name></person-group>
<year>2012</year>
<article-title>Validation of the multiple sensor mechanism of the Keap1-Nrf2 system</article-title>. <source/>Free Radic. Biol. Med.
<volume>53</volume>, <fpage>817</fpage>–<lpage>827</lpage>. (<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.06.023</pub-id>)<pub-id pub-id-type="pmid">22732183</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C74">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Eggler</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Mesecar</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>van Breemen</surname><given-names>RB.</given-names></name></person-group>
<year>2011</year>
<article-title>Modification of keap1 cysteine residues by sulforaphane</article-title>. <source/>Chem. Res. Toxicol.
<volume>24</volume>, <fpage>515</fpage>–<lpage>521</lpage>. (<pub-id pub-id-type="doi">10.1021/tx100389r</pub-id>)<pub-id pub-id-type="pmid">21391649</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C75">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dayalan Naidu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fahey</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name></person-group>
<year>2018</year>
<article-title>Phenethyl isothiocyanate, a dual activator of transcription factors NRF2 and HSF1</article-title>. <source/>Mol. Nutr. Food Res.
<volume>62</volume>, <fpage>e1700908</fpage> (<pub-id pub-id-type="doi">10.1002/mnfr.201700908</pub-id>)<pub-id pub-id-type="pmid">29710398</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C76">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brennan</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Matos</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hronowski</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Juhasz</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Rhodes</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Scannevin</surname><given-names>RH</given-names></name></person-group>
<year>2015</year>
<article-title>Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro</article-title>. <source/>PLoS ONE
<volume>10</volume>, <fpage>e0120254</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0120254</pub-id>)<pub-id pub-id-type="pmid">25793262</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C77">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>
<year>2019</year>
<article-title>Molecular mechanism of cellular oxidative stress sensing by Keap1</article-title>. <source/>Cell Rep.
<volume>28</volume>, <fpage>746</fpage>–<lpage>758</lpage>. (<pub-id pub-id-type="doi">10.1016/j.celrep.2019.06.047</pub-id>)<pub-id pub-id-type="pmid">31315052</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C78">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hourihan</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Kenna</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Hayes</surname><given-names>JD</given-names></name></person-group>
<year>2013</year>
<article-title>The gasotransmitter hydrogen sulfide induces Nrf2-target genes by inactivating the Keap1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between Cys-226 and Cys-613</article-title>. <source/>Antioxid Redox Signal.
<volume>19</volume>, <fpage>465</fpage>–<lpage>481</lpage>. (<pub-id pub-id-type="doi">10.1089/ars.2012.4944</pub-id>)<pub-id pub-id-type="pmid">23145493</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C79">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2009</year>
<article-title>The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds</article-title>. <source/>Mol. Cell Biol.
<volume>29</volume>, <fpage>493</fpage>–<lpage>502</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.01080-08</pub-id>)<pub-id pub-id-type="pmid">19001094</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C80">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujii</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<year>2010</year>
<article-title>The critical role of nitric oxide signaling, via protein S-guanylation and nitrated cyclic GMP, in the antioxidant adaptive response</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>23 970</fpage>–<lpage>23 984</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M110.145441</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C81">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMahon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Swift</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Hayes</surname><given-names>JD</given-names></name></person-group>
<year>2018</year>
<article-title>Zinc-binding triggers a conformational-switch in the cullin-3 substrate adaptor protein KEAP1 that controls transcription factor NRF2</article-title>. <source/>Toxicol. Appl. Pharmacol.
<volume>360</volume>, <fpage>45</fpage>–<lpage>57</lpage>. (<pub-id pub-id-type="doi">10.1016/j.taap.2018.09.033</pub-id>)<pub-id pub-id-type="pmid">30261176</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C82">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumagai</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kanda</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shinkai</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Toyama</surname><given-names>T</given-names></name></person-group>
<year>2013</year>
<article-title>The role of the Keap1/Nrf2 pathway in the cellular response to methylmercury</article-title>. <source/>Oxid. Med. Cell Longev.
<volume>2013</volume>, <fpage>848279</fpage> (<pub-id pub-id-type="doi">10.1155/2013/848279</pub-id>)<pub-id pub-id-type="pmid">23878621</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C83">
<label>83</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinkai</surname><given-names>Y</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Reactive sulfur species-mediated activation of the Keap1-Nrf2 pathway by 1,2-Naphthoquinone through sulfenic acids formation under oxidative stress</article-title>. <source/>Chem. Res. Toxicol.
<volume>28</volume>, <fpage>838</fpage>–<lpage>847</lpage>. (<pub-id pub-id-type="doi">10.1021/tx500416y</pub-id>)<pub-id pub-id-type="pmid">25807370</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C84">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinti</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>114</volume>, <fpage>E4676</fpage>-<lpage>E4685</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.1614943114</pub-id>)<pub-id pub-id-type="pmid">28533375</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C85">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietz</surname><given-names>BM</given-names></name><etal>et al</etal></person-group>
<year>2008</year>
<article-title>Angelica sinensis and its alkylphthalides induce the detoxification enzyme NAD(P)H: quinone oxidoreductase 1 by alkylating Keap1</article-title>. <source/>Chem. Res. Toxicol.
<volume>21</volume>, <fpage>1939</fpage>–<lpage>1948</lpage>. (<pub-id pub-id-type="doi">10.1021/tx8001274</pub-id>)<pub-id pub-id-type="pmid">18808158</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C86">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>HG</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Kundu</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Keum</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Cha</surname><given-names>YN</given-names></name>, <name name-style="western"><surname>Na</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Surh</surname><given-names>YJ</given-names></name></person-group>
<year>2014</year>
<article-title>Keap1 cysteine 288 as a potential target for diallyl trisulfide-induced Nrf2 activation</article-title>. <source/>PLoS ONE
<volume>9</volume>, <fpage>e85984</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0085984</pub-id>)<pub-id pub-id-type="pmid">24489685</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C87">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Copple</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Goldring</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Jenkins</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Chia</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Randle</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Hayes</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Kitteringham</surname><given-names>NR</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>BK</given-names></name></person-group>
<year>2008</year>
<article-title>The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system</article-title>. <source/>Hepatology
<volume>48</volume>, <fpage>1292</fpage>–<lpage>1301</lpage>. (<pub-id pub-id-type="doi">10.1002/hep.22472</pub-id>)<pub-id pub-id-type="pmid">18785192</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C88">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Eggler</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mesecar</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>van Breemen</surname><given-names>RB.</given-names></name></person-group>
<year>2007</year>
<article-title>Sites of alkylation of human Keap1 by natural chemoprevention agents</article-title>. <source/>J. Am. Soc. Mass Spectrom.
<volume>18</volume>, <fpage>2226</fpage>–<lpage>2232</lpage>. (<pub-id pub-id-type="doi">10.1016/j.jasms.2007.09.015</pub-id>)<pub-id pub-id-type="pmid">17980616</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C89">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Sekhar</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Freeman</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Liebler</surname><given-names>DC</given-names></name></person-group>
<year>2005</year>
<article-title>Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation</article-title>. <source/>J. Biol. Chem.
<volume>280</volume>, <fpage>31 768</fpage>–<lpage>31 775</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M503346200</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C90">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakurai</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kanayama</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shibata</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Itoh</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Uchida</surname><given-names>K</given-names></name></person-group>
<year>2006</year>
<article-title>Ebselen, a seleno-organic antioxidant, as an electrophile</article-title>. <source/>Chem. Res. Toxicol.
<volume>19</volume>, <fpage>1196</fpage>–<lpage>1204</lpage>. (<pub-id pub-id-type="doi">10.1021/tx0601105</pub-id>)<pub-id pub-id-type="pmid">16978024</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C91">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holland</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hawkins</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Eggler</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Mesecar</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Fabris</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fishbein</surname><given-names>JC</given-names></name></person-group>
<year>2008</year>
<article-title>Prospective type 1 and type 2 disulfides of Keap1 protein</article-title>. <source/>Chem. Res. Toxicol.
<volume>21</volume>, <fpage>2051</fpage>–<lpage>2060</lpage>. (<pub-id pub-id-type="doi">10.1021/tx800226m</pub-id>)<pub-id pub-id-type="pmid">18729328</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C92">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryan</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Olayanju</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Goldring</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>BK</given-names></name></person-group>
<year>2013</year>
<article-title>The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation</article-title>. <source/>Biochem. Pharmacol.
<volume>85</volume>, <fpage>705</fpage>–<lpage>717</lpage>. (<pub-id pub-id-type="doi">10.1016/j.bcp.2012.11.016</pub-id>)<pub-id pub-id-type="pmid">23219527</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C93">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Okawa</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ohtsuji</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zenke</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chiba</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Igarashi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name></person-group>
<year>2004</year>
<article-title>Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2</article-title>. <source/>Mol. Cell Biol.
<volume>24</volume>, <fpage>7130</fpage>–<lpage>7139</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.24.16.7130-7139.2004</pub-id>)<pub-id pub-id-type="pmid">15282312</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C94">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Miao</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Batist</surname><given-names>G</given-names></name></person-group>
<year>2010</year>
<article-title>Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1</article-title>. <source/>Chem. Biol. Drug Des.
<volume>75</volume>, <fpage>475</fpage>–<lpage>480</lpage>. (<pub-id pub-id-type="doi">10.1111/j.1747-0285.2010.00955.x</pub-id>)<pub-id pub-id-type="pmid">20486933</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C95">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levonen</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Landar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ramachandran</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ceaser</surname><given-names>EK</given-names></name>, <name name-style="western"><surname>Dickinson</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Zanoni</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Morrow</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Darley-Usmar</surname><given-names>VM</given-names></name></person-group>
<year>2004</year>
<article-title>Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products</article-title>. <source/>Biochem. J.
<volume>378</volume>, <fpage>373</fpage>–<lpage>382</lpage>. (<pub-id pub-id-type="doi">10.1042/BJ20031049</pub-id>)<pub-id pub-id-type="pmid">14616092</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C96">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wakabayashi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Holtzclaw</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kensler</surname><given-names>TW</given-names></name>, <name name-style="western"><surname>Talalay</surname><given-names>P</given-names></name></person-group>
<year>2004</year>
<article-title>Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>101</volume>, <fpage>2040</fpage>–<lpage>2045</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0307301101</pub-id>)<pub-id pub-id-type="pmid">14764894</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C97">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group>
<year>2009</year>
<article-title>I-TASSER: fully automated protein structure prediction in CASP8</article-title>. <source/>Proteins
<volume>77</volume>(<issue>Suppl. 9</issue>), <fpage>100</fpage>–<lpage>113</lpage>. (<pub-id pub-id-type="doi">10.1002/prot.22588</pub-id>)<pub-id pub-id-type="pmid">19768687</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C98">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group>
<year>2012</year>
<article-title>COFACTOR: an accurate comparative algorithm for structure-based protein function annotation</article-title>. <source/>Nucleic Acids Res.
<volume>40</volume>, <fpage>W471</fpage>–<lpage>W477</lpage>. (<pub-id pub-id-type="doi">10.1093/nar/gks372</pub-id>)<pub-id pub-id-type="pmid">22570420</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C99">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group>
<year>2015</year>
<article-title>I-TASSER server: new development for protein structure and function predictions</article-title>. <source/>Nucleic Acids Res.
<volume>43</volume>, <fpage>W174</fpage>–<lpage>W181</lpage>. (<pub-id pub-id-type="doi">10.1093/nar/gkv342</pub-id>)<pub-id pub-id-type="pmid">25883148</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C100">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hannink</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Beamer</surname><given-names>LJ</given-names></name></person-group>
<year>2004</year>
<article-title>Crystal structure of the Kelch domain of human Keap1</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <fpage>54 750</fpage>–<lpage>54 758</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M410073200</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C101">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Henzl</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Beamer</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Hannink</surname><given-names>M</given-names></name></person-group>
<year>2006</year>
<article-title>Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling</article-title>. <source/>EMBO J.
<volume>25</volume>, <fpage>3605</fpage>–<lpage>3617</lpage>. (<pub-id pub-id-type="doi">10.1038/sj.emboj.7601243</pub-id>)<pub-id pub-id-type="pmid">16888629</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C102">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>KI</given-names></name>, <name name-style="western"><surname>Padmanabhan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hirotsu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yokoyama</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name></person-group>
<year>2007</year>
<article-title>Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response</article-title>. <source/>Mol. Cell Biol.
<volume>27</volume>, <fpage>7511</fpage>–<lpage>7521</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.00753-07</pub-id>)<pub-id pub-id-type="pmid">17785452</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C103">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Komatsu</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2010</year>
<article-title>The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1</article-title>. <source/>Nat. Cell Biol.
<volume>12</volume>, <fpage>213</fpage>–<lpage>223</lpage>. (<pub-id pub-id-type="doi">10.1038/ncb2021</pub-id>)<pub-id pub-id-type="pmid">20173742</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C104">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukutomi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Takagi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mizushima</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ohuchi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name></person-group>
<year>2014</year>
<article-title>Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1</article-title>. <source/>Mol. Cell Biol.
<volume>34</volume>, <fpage>832</fpage>–<lpage>846</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.01191-13</pub-id>)<pub-id pub-id-type="pmid">24366543</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C105">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winkel</surname><given-names>AF</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Characterization of RA839, a noncovalent small molecule binder to Keap1 and selective activator of Nrf2 signaling</article-title>. <source/>J. Biol. Chem.
<volume>290</volume>, <fpage>28 446</fpage>–<lpage>28 455</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M115.678136</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C106">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>TG</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>Monoacidic inhibitors of the Kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction with high cell potency identified by fragment-based discovery</article-title>. <source/>J. Med. Chem.
<volume>59</volume>, <fpage>3991</fpage>–<lpage>4006</lpage>. (<pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00228</pub-id>)<pub-id pub-id-type="pmid">27031670</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C107">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming</article-title>. <source/>Nat. Commun.
<volume>7</volume>, <fpage>12030</fpage> (<pub-id pub-id-type="doi">10.1038/ncomms12030</pub-id>)<pub-id pub-id-type="pmid">27345495</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C108">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canning</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sorrell</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Bullock</surname><given-names>AN</given-names></name></person-group>
<year>2015</year>
<article-title>Structural basis of Keap1 interactions with Nrf2</article-title>. <source/>Free Radic. Biol. Med.
<volume>88</volume>, <fpage>101</fpage>–<lpage>107</lpage>. (<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.05.034</pub-id>)<pub-id pub-id-type="pmid">26057936</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C109">
<label>109</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMahon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Itoh</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hayes</surname><given-names>JD</given-names></name></person-group>
<year>2004</year>
<article-title>Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <fpage>31 556</fpage>–<lpage>31 567</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M403061200</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C110">
<label>110</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMahon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Itoh</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hayes</surname><given-names>JD</given-names></name></person-group>
<year>2006</year>
<article-title>Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a ‘tethering’ mechanism: a two-site interaction model for the Nrf2-Keap1 complex</article-title>. <source/>J. Biol. Chem.
<volume>281</volume>, <fpage>24 756</fpage>–<lpage>24 768</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M601119200</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C111">
<label>111</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>KI</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Katsuoka</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name></person-group>
<year>2006</year>
<article-title>Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism</article-title>. <source/>Biol. Chem.
<volume>387</volume>, <fpage>1311</fpage>–<lpage>1320</lpage>. (<pub-id pub-id-type="doi">10.1515/BC.2006.164</pub-id>)<pub-id pub-id-type="pmid">17081101</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C112">
<label>112</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>G</given-names></name></person-group>
<year>2015</year>
<article-title>Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction</article-title>. <source/>Biochem. Soc. Trans.
<volume>43</volume>, <fpage>674</fpage>–<lpage>679</lpage>. (<pub-id pub-id-type="doi">10.1042/BST20150051</pub-id>)<pub-id pub-id-type="pmid">26551711</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C113">
<label>113</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertrand</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Schaap</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Baird</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Georgakopoulos</surname><given-names>ND</given-names></name>, <name name-style="western"><surname>Fowkes</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Thiollier</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kachi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Wells</surname><given-names>G</given-names></name></person-group>
<year>2015</year>
<article-title>Design, synthesis, and evaluation of triazole derivatives that induce Nrf2 dependent gene products and inhibit the Keap1-Nrf2 protein-protein interaction</article-title>. <source/>J. Med. Chem.
<volume>58</volume>, <fpage>7186</fpage>–<lpage>7194</lpage>. (<pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00602</pub-id>)<pub-id pub-id-type="pmid">26348784</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C114">
<label>114</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogura</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tong</surname><given-names>KI</given-names></name>, <name name-style="western"><surname>Mio</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Maruyama</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kurokawa</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name></person-group>
<year>2010</year>
<article-title>Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>107</volume>, <fpage>2842</fpage>–<lpage>2847</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0914036107</pub-id>)<pub-id pub-id-type="pmid">20133743</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C115">
<label>115</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarikas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hartmann</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>ZQ</given-names></name></person-group>
<year>2011</year>
<article-title>The cullin protein family</article-title>. <source/>Genome Biol.
<volume>12</volume>, <fpage>220</fpage> (<pub-id pub-id-type="doi">10.1186/gb-2011-12-4-220</pub-id>)<pub-id pub-id-type="pmid">21554755</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C116">
<label>116</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderica-Romero</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Gonzalez-Herrera</surname><given-names>IG</given-names></name>, <name name-style="western"><surname>Santamaria</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pedraza-Chaverri</surname><given-names>J</given-names></name></person-group>
<year>2013</year>
<article-title>Cullin 3 as a novel target in diverse pathologies</article-title>. <source/>Redox Biol.
<volume>1</volume>, <fpage>366</fpage>–<lpage>372</lpage>. (<pub-id pub-id-type="doi">10.1016/j.redox.2013.07.003</pub-id>)<pub-id pub-id-type="pmid">24024173</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C117">
<label>117</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cullinan</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Gordan</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Harper</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Diehl</surname><given-names>JA</given-names></name></person-group>
<year>2004</year>
<article-title>The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase</article-title>. <source/>Mol. Cell Biol.
<volume>24</volume>, <fpage>8477</fpage>–<lpage>8486</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.24.19.8477-8486.2004</pub-id>)<pub-id pub-id-type="pmid">15367669</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C118">
<label>118</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>HF</given-names></name>, <name name-style="western"><surname>Tomida</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Koshimizu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ogiso</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tsuruo</surname><given-names>T</given-names></name></person-group>
<year>2004</year>
<article-title>Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex</article-title>. <source/>Cancer Res.
<volume>64</volume>, <fpage>1114</fpage>–<lpage>1121</lpage>. (<pub-id pub-id-type="doi">10.1158/0008-5472.can-03-2858</pub-id>)<pub-id pub-id-type="pmid">14871846</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C119">
<label>119</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furukawa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Xiong</surname><given-names>Y</given-names></name></person-group>
<year>2005</year>
<article-title>BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase</article-title>. <source/>Mol. Cell Biol.
<volume>25</volume>, <fpage>162</fpage>–<lpage>171</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.25.1.162-171.2005</pub-id>)<pub-id pub-id-type="pmid">15601839</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C120">
<label>120</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choo</surname><given-names>YY</given-names></name>, <name name-style="western"><surname>Hagen</surname><given-names>T</given-names></name></person-group>
<year>2012</year>
<article-title>Mechanism of cullin3 E3 ubiquitin ligase dimerization</article-title>. <source/>PLoS ONE
<volume>7</volume>, <fpage>e41350</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0041350</pub-id>)<pub-id pub-id-type="pmid">22911784</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C121">
<label>121</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sporn</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Liby</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Yore</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lopchuk</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Gribble</surname><given-names>GW</given-names></name></person-group>
<year>2011</year>
<article-title>New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress</article-title>. <source/>J. Nat. Prod.
<volume>74</volume>, <fpage>537</fpage>–<lpage>545</lpage>. (<pub-id pub-id-type="doi">10.1021/np100826q</pub-id>)<pub-id pub-id-type="pmid">21309592</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C122">
<label>122</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Rounds</surname><given-names>BV</given-names></name>, <name name-style="western"><surname>Bore</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Finlay</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Favaloro</surname><given-names>FG</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Suh</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sporn</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Gribble</surname><given-names>GW</given-names></name></person-group>
<year>2000</year>
<article-title>Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages</article-title>. <source/>J. Med. Chem.
<volume>43</volume>, <fpage>4233</fpage>–<lpage>4246</lpage>. (<pub-id pub-id-type="doi">10.1021/jm0002230</pub-id>)<pub-id pub-id-type="pmid">11063620</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C123">
<label>123</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Honda</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Favaloro</surname><given-names>FG</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Gribble</surname><given-names>GW</given-names></name>, <name name-style="western"><surname>Suh</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Place</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Rendi</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Sporn</surname><given-names>MB</given-names></name></person-group>
<year>2002</year>
<article-title>A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production</article-title>. <source/>Bioorg. Med. Chem. Lett.
<volume>12</volume>, <fpage>1027</fpage>–<lpage>1030</lpage>. (<pub-id pub-id-type="doi">10.1016/s0960-894x(02)00105-1</pub-id>)<pub-id pub-id-type="pmid">11909709</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C124">
<label>124</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>QX</given-names></name>, <name name-style="western"><surname>Onyango</surname><given-names>EO</given-names></name>, <name name-style="western"><surname>Liby</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Sporn</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Gribble</surname><given-names>GW</given-names></name></person-group>
<year>2017</year>
<article-title>Design, synthesis, and biological activity of second-generation synthetic oleanane triterpenoids</article-title>. <source/>Org. Biomol. Chem.
<volume>15</volume>, <fpage>6001</fpage>–<lpage>6005</lpage>. (<pub-id pub-id-type="doi">10.1039/c7ob01420a</pub-id>)<pub-id pub-id-type="pmid">28678272</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C125">
<label>125</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Couch</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Browning</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Honda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gribble</surname><given-names>GW</given-names></name>, <name name-style="western"><surname>Wright</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Sporn</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>AC</given-names></name></person-group>
<year>2005</year>
<article-title>Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action</article-title>. <source/>Bioorg. Med. Chem. Lett.
<volume>15</volume>, <fpage>2215</fpage>–<lpage>2219</lpage>. (<pub-id pub-id-type="doi">10.1016/j.bmcl.2005.03.031</pub-id>)<pub-id pub-id-type="pmid">15837296</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C126">
<label>126</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reisman</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Gahir</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>CI</given-names></name>, <name name-style="western"><surname>Proksch</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Sakamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>KW</given-names></name></person-group>
<year>2019</year>
<article-title>Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates</article-title>. <source/>Drug Des. Dev. Ther.
<volume>13</volume>, <fpage>1259</fpage>–<lpage>1270</lpage>. (<pub-id pub-id-type="doi">10.2147/DDDT.S193889</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C127">
<label>127</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lynch</surname><given-names>DR</given-names></name><etal>et al.</etal></person-group>
<year>2019</year>
<article-title>Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia</article-title>. <source/>Ann. Clin. Transl. Neurol.
<volume>6</volume>, <fpage>15</fpage>–<lpage>26</lpage>. (<pub-id pub-id-type="doi">10.1002/acn3.660</pub-id>)<pub-id pub-id-type="pmid">30656180</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C128">
<label>128</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Creelan</surname><given-names>BC</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors</article-title>. <source/>Onco Targets Ther.
<volume>10</volume>, <fpage>4239</fpage>–<lpage>4250</lpage>. (<pub-id pub-id-type="doi">10.2147/OTT.S136992</pub-id>)<pub-id pub-id-type="pmid">28919776</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C129">
<label>129</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Favaloro</surname><given-names>FG</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Honda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Honda</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gribble</surname><given-names>GW</given-names></name>, <name name-style="western"><surname>Suh</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Risingsong</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sporn</surname><given-names>MB</given-names></name></person-group>
<year>2002</year>
<article-title>Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages</article-title>. <source/>J. Med. Chem.
<volume>45</volume>, <fpage>4801</fpage>–<lpage>4805</lpage>. (<pub-id pub-id-type="doi">10.1021/jm025565f</pub-id>)<pub-id pub-id-type="pmid">12383005</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C130">
<label>130</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents</article-title>. <source/>J. Med. Chem.
<volume>54</volume>, <fpage>1762</fpage>–<lpage>1778</lpage>. (<pub-id pub-id-type="doi">10.1021/jm101445p</pub-id>)<pub-id pub-id-type="pmid">21361338</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C131">
<label>131</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents</article-title>. <source/>J. Med. Chem.
<volume>55</volume>, <fpage>4837</fpage>–<lpage>4846</lpage>. (<pub-id pub-id-type="doi">10.1021/jm3003922</pub-id>)<pub-id pub-id-type="pmid">22533790</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C132">
<label>132</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name><etal>et al.</etal></person-group>
<year>2005</year>
<article-title>Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>102</volume>, <fpage>4584</fpage>–<lpage>4589</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0500815102</pub-id>)<pub-id pub-id-type="pmid">15767573</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C133">
<label>133</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Talalay</surname><given-names>P</given-names></name></person-group>
<year>2008</year>
<article-title>Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>105</volume>, <fpage>15 926</fpage>–<lpage>15 931</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0808346105</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C134">
<label>134</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yates</surname><given-names>MS</given-names></name><etal>et al.</etal></person-group>
<year>2007</year>
<article-title>Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes</article-title>. <source/>Mol. Cancer Ther.
<volume>6</volume>, <fpage>154</fpage>–<lpage>162</lpage>. (<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0516</pub-id>)<pub-id pub-id-type="pmid">17237276</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C135">
<label>135</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>David</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Padegimas</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Sundararajan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Visnick</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bumeister</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Christian Wigley</surname><given-names>W</given-names></name></person-group>
<year>2011</year>
<article-title>Synthesis and biological evaluation of 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent</article-title>. <source/>Bioorg. Med. Chem. Lett.
<volume>21</volume>, <fpage>2188</fpage>–<lpage>2191</lpage>. (<pub-id pub-id-type="doi">10.1016/j.bmcl.2011.03.018</pub-id>)<pub-id pub-id-type="pmid">21441026</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C136">
<label>136</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liby</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<year>2008</year>
<article-title>A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin</article-title>. <source/>Cancer Res.
<volume>68</volume>, <fpage>6727</fpage>–<lpage>6733</lpage>. (<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1123</pub-id>)<pub-id pub-id-type="pmid">18701497</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C137">
<label>137</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sundararajan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yoshizawa</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Honda</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liby</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Sporn</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Gribble</surname><given-names>GW</given-names></name></person-group>
<year>2007</year>
<article-title>Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents</article-title>. <source/>J. Med. Chem.
<volume>50</volume>, <fpage>1731</fpage>–<lpage>1734</lpage>. (<pub-id pub-id-type="doi">10.1021/jm070141c</pub-id>)<pub-id pub-id-type="pmid">17367124</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C138">
<label>138</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name><etal>et al.</etal></person-group>
<year>2010</year>
<article-title>An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>33 747</fpage>–<lpage>33 755</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M110.163485</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB200105C139">
<label>139</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kostov</surname><given-names>RV</given-names></name>, <name name-style="western"><surname>Knatko</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>McLaughlin</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Henderson</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Honda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name></person-group>
<year>2015</year>
<article-title>Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>465</volume>, <fpage>402</fpage>–<lpage>407</lpage>. (<pub-id pub-id-type="doi">10.1016/j.bbrc.2015.08.016</pub-id>)<pub-id pub-id-type="pmid">26265043</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C140">
<label>140</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>New monocyclic, bicyclic, and tricyclic ethynylcyanodienones as activators of the Keap1/Nrf2/ARE pathway and inhibitors of inducible nitric oxide synthase</article-title>. <source/>J. Med. Chem.
<volume>58</volume>, <fpage>4738</fpage>–<lpage>4748</lpage>. (<pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00393</pub-id>)<pub-id pub-id-type="pmid">25965897</pub-id></mixed-citation>
</ref>
<ref id="RSOB200105C141">
<label>141</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>W</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>Antidepressant effects of TBE-31 and MCE-1, the novel Nrf2 activators, in an inflammation model of depression</article-title>. <source/>Eur. J. Pharmacol.
<volume>793</volume>, <fpage>21</fpage>–<lpage>27</lpage>. (<pub-id pub-id-type="doi">10.1016/j.ejphar.2016.10.037</pub-id>)<pub-id pub-id-type="pmid">27815170</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>